AU2022396272A1 - Antibodies against ctla-4 and methods of use thereof - Google Patents
Antibodies against ctla-4 and methods of use thereof Download PDFInfo
- Publication number
- AU2022396272A1 AU2022396272A1 AU2022396272A AU2022396272A AU2022396272A1 AU 2022396272 A1 AU2022396272 A1 AU 2022396272A1 AU 2022396272 A AU2022396272 A AU 2022396272A AU 2022396272 A AU2022396272 A AU 2022396272A AU 2022396272 A1 AU2022396272 A1 AU 2022396272A1
- Authority
- AU
- Australia
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 87
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims abstract description 484
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims abstract description 309
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract description 297
- 102000043321 human CTLA4 Human genes 0.000 claims abstract description 174
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2590
- 230000027455 binding Effects 0.000 claims description 168
- 108091007433 antigens Proteins 0.000 claims description 164
- 102000036639 antigens Human genes 0.000 claims description 164
- 239000000427 antigen Substances 0.000 claims description 162
- 239000012634 fragment Substances 0.000 claims description 158
- 210000004027 cell Anatomy 0.000 claims description 140
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
- 150000001413 amino acids Chemical class 0.000 claims description 50
- 229920001184 polypeptide Polymers 0.000 claims description 50
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 47
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 46
- 150000007523 nucleic acids Chemical class 0.000 claims description 44
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 36
- -1 ICOS Proteins 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 30
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 26
- 210000000822 natural killer cell Anatomy 0.000 claims description 25
- 102000004127 Cytokines Human genes 0.000 claims description 17
- 108090000695 Cytokines Proteins 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 16
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 16
- 230000004068 intracellular signaling Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 10
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 10
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 210000002865 immune cell Anatomy 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 7
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 150000003384 small molecules Chemical class 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 7
- 108700012359 toxins Proteins 0.000 claims description 7
- 108010029697 CD40 Ligand Proteins 0.000 claims description 6
- 102100032937 CD40 ligand Human genes 0.000 claims description 6
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 5
- 102100038078 CD276 antigen Human genes 0.000 claims description 5
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 5
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 5
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 5
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 5
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 5
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 claims description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 5
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 5
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 5
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 5
- 102100034980 ICOS ligand Human genes 0.000 claims description 5
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 5
- 108020003285 Isocitrate lyase Proteins 0.000 claims description 5
- 102000017578 LAG3 Human genes 0.000 claims description 5
- 101150030213 Lag3 gene Proteins 0.000 claims description 5
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 claims description 5
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 claims description 5
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 5
- 108010042215 OX40 Ligand Proteins 0.000 claims description 5
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 5
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 claims description 5
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 5
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 5
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 5
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000010445 mica Substances 0.000 claims description 5
- 229910052618 mica group Inorganic materials 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims description 3
- 102100032976 CCR4-NOT transcription complex subunit 6 Human genes 0.000 claims description 3
- 102000002698 KIR Receptors Human genes 0.000 claims description 3
- 108010043610 KIR Receptors Proteins 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 78
- 241000282414 Homo sapiens Species 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 63
- 235000018102 proteins Nutrition 0.000 description 60
- 235000001014 amino acid Nutrition 0.000 description 39
- 108060003951 Immunoglobulin Proteins 0.000 description 34
- 102000018358 immunoglobulin Human genes 0.000 description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 239000000203 mixture Substances 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 29
- 125000005647 linker group Chemical group 0.000 description 26
- 108020001507 fusion proteins Proteins 0.000 description 22
- 102000037865 fusion proteins Human genes 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 229960005386 ipilimumab Drugs 0.000 description 22
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 21
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 21
- 230000004927 fusion Effects 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 230000028993 immune response Effects 0.000 description 17
- 230000000670 limiting effect Effects 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 15
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 15
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000000295 complement effect Effects 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 230000002829 reductive effect Effects 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 14
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 13
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 230000008685 targeting Effects 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 10
- 208000006265 Renal cell carcinoma Diseases 0.000 description 10
- 239000000539 dimer Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 239000013603 viral vector Substances 0.000 description 10
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 238000002659 cell therapy Methods 0.000 description 9
- 238000010494 dissociation reaction Methods 0.000 description 9
- 230000005593 dissociations Effects 0.000 description 9
- 239000012636 effector Substances 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 208000030808 Clear cell renal carcinoma Diseases 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 230000009977 dual effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000013595 glycosylation Effects 0.000 description 8
- 238000006206 glycosylation reaction Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 229940127089 cytotoxic agent Drugs 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 239000012491 analyte Substances 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241001430294 unidentified retrovirus Species 0.000 description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 5
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 5
- 108090000172 Interleukin-15 Proteins 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000013401 experimental design Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 241000702421 Dependoparvovirus Species 0.000 description 4
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 102100039554 Galectin-8 Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 4
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 102100034256 Mucin-1 Human genes 0.000 description 4
- 101100222220 Mus musculus Ctla4 gene Proteins 0.000 description 4
- 102000004473 OX40 Ligand Human genes 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 238000002617 apheresis Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 239000002254 cytotoxic agent Substances 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000016784 immunoglobulin production Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000003094 microcapsule Substances 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical class [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 3
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 102100030698 Interleukin-12 subunit alpha Human genes 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100025096 Mesothelin Human genes 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940124452 immunizing agent Drugs 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- VPKDCDLSJZCGKE-UHFFFAOYSA-N methanediimine Chemical compound N=C=N VPKDCDLSJZCGKE-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 108091007743 BRCA1/2 Proteins 0.000 description 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 102100025221 CD70 antigen Human genes 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102100038447 Claudin-4 Human genes 0.000 description 2
- 102000057710 Coatomer Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101150029707 ERBB2 gene Proteins 0.000 description 2
- 101710130332 ETS domain-containing protein Elk-4 Proteins 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 241000714165 Feline leukemia virus Species 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000882890 Homo sapiens Claudin-4 Proteins 0.000 description 2
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 2
- 101000981680 Homo sapiens Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Proteins 0.000 description 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 description 2
- 101710187487 Interleukin-12 subunit beta Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102100024102 Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Human genes 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 101150064776 Msln gene Proteins 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710138742 Receptor-type tyrosine-protein phosphatase H Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 102400000830 Saposin-B Human genes 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 108010002687 Survivin Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 101710199837 Terminal uridylyltransferase 1 Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 101000642183 Trypanosoma brucei brucei Terminal uridylyltransferase 2 Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 238000013357 binding ELISA Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960000106 biosimilars Drugs 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 108700010039 chimeric receptor Proteins 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000004754 hybrid cell Anatomy 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229960004961 mechlorethamine Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 238000012737 microarray-based gene expression Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 229950002142 minretumomab Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108010079891 prostein Proteins 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000016914 ras Proteins Human genes 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 101150047061 tag-72 gene Proteins 0.000 description 2
- 238000012956 testing procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229950007217 tremelimumab Drugs 0.000 description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- QYEAAMBIUQLHFQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 QYEAAMBIUQLHFQ-UHFFFAOYSA-N 0.000 description 1
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- IEUUDEWWMRQUDS-UHFFFAOYSA-N (6-azaniumylidene-1,6-dimethoxyhexylidene)azanium;dichloride Chemical compound Cl.Cl.COC(=N)CCCCC(=N)OC IEUUDEWWMRQUDS-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VILFTWLXLYIEMV-UHFFFAOYSA-N 1,5-difluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=C(F)C=C1F VILFTWLXLYIEMV-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- YBBNVCVOACOHIG-UHFFFAOYSA-N 2,2-diamino-1,4-bis(4-azidophenyl)-3-butylbutane-1,4-dione Chemical compound C=1C=C(N=[N+]=[N-])C=CC=1C(=O)C(N)(N)C(CCCC)C(=O)C1=CC=C(N=[N+]=[N-])C=C1 YBBNVCVOACOHIG-UHFFFAOYSA-N 0.000 description 1
- ASNTZYQMIUCEBV-UHFFFAOYSA-N 2,5-dioxo-1-[6-[3-(pyridin-2-yldisulfanyl)propanoylamino]hexanoyloxy]pyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCCCNC(=O)CCSSC1=CC=CC=N1 ASNTZYQMIUCEBV-UHFFFAOYSA-N 0.000 description 1
- FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
- FBUTXZSKZCQABC-UHFFFAOYSA-N 2-amino-1-methyl-7h-purine-6-thione Chemical compound S=C1N(C)C(N)=NC2=C1NC=N2 FBUTXZSKZCQABC-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- CQXXYOLFJXSRMT-UHFFFAOYSA-N 5-diazocyclohexa-1,3-diene Chemical class [N-]=[N+]=C1CC=CC=C1 CQXXYOLFJXSRMT-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 241000714188 Friend murine leukemia virus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 241000696272 Gull adenovirus Species 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000605076 Homo sapiens Ligand-dependent nuclear receptor corepressor-like protein Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 101710194995 Interleukin-12 subunit alpha Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100038259 Ligand-dependent nuclear receptor corepressor-like protein Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 244000302512 Momordica charantia Species 0.000 description 1
- 235000009811 Momordica charantia Nutrition 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 108010033737 Pokeweed Mitogens Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000713675 Spumavirus Species 0.000 description 1
- 241000269319 Squalius cephalus Species 0.000 description 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 240000001866 Vernicia fordii Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 229950005186 abagovomab Drugs 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- OFLXLNCGODUUOT-UHFFFAOYSA-N acetohydrazide Chemical class C\C(O)=N\N OFLXLNCGODUUOT-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229950009084 adecatumumab Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005599 alkyl carboxylate group Chemical group 0.000 description 1
- 108010001818 alpha-sarcin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229950009106 altumomab Drugs 0.000 description 1
- 229950001537 amatuximab Drugs 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229950005725 arcitumomab Drugs 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229950007843 bavituximab Drugs 0.000 description 1
- 229950003269 bectumomab Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229950002903 bivatuzumab Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229960003008 blinatumomab Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229960000455 brentuximab vedotin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000419 catumaxomab Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 229960002559 chlorotrianisene Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229950006647 cixutumumab Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229950007276 conatumumab Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229950007409 dacetuzumab Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002482 dalotuzumab Drugs 0.000 description 1
- 229960002204 daratumumab Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229950008962 detumomab Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229930191339 dianthin Natural products 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- NLORYLAYLIXTID-ISLYRVAYSA-N diethylstilbestrol diphosphate Chemical compound C=1C=C(OP(O)(O)=O)C=CC=1C(/CC)=C(\CC)C1=CC=C(OP(O)(O)=O)C=C1 NLORYLAYLIXTID-ISLYRVAYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229950009964 drozitumab Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229950011453 dusigitumab Drugs 0.000 description 1
- 229950000006 ecromeximab Drugs 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229960004137 elotuzumab Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 108010028531 enomycin Proteins 0.000 description 1
- 229950010640 ensituximab Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229950008579 ertumaxomab Drugs 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001766 estramustine phosphate sodium Drugs 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229950009569 etaracizumab Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950009929 farletuzumab Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 229950008085 figitumumab Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229950010320 flanvotumab Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960000297 fosfestrol Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-M fusidate Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C([O-])=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-M 0.000 description 1
- 229950002140 futuximab Drugs 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 229950004896 ganitumab Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229950002026 girentuximab Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229950000918 glembatumumab Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229950002200 igovomab Drugs 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000020287 immunological synapse formation Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 108091008042 inhibitory receptors Proteins 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
- 229950001014 intetumumab Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229950010939 iratumumab Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 229950000518 labetuzumab Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 229950002950 lintuzumab Drugs 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950004563 lucatumumab Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229950008001 matuzumab Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- DFTAZNAEBRBBKP-UHFFFAOYSA-N methyl 4-sulfanylbutanimidate Chemical compound COC(=N)CCCS DFTAZNAEBRBBKP-UHFFFAOYSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 229950003734 milatuzumab Drugs 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229960000513 necitumumab Drugs 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 229950010203 nimotuzumab Drugs 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229950009090 ocaratuzumab Drugs 0.000 description 1
- 229960002450 ofatumumab Drugs 0.000 description 1
- 229950008516 olaratumab Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229950007283 oregovomab Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 201000008017 ovarian lymphoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 229950004260 parsatuzumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229950010966 patritumab Drugs 0.000 description 1
- 229960005570 pemtumomab Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 108010076042 phenomycin Proteins 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229940126620 pintumomab Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229950008885 polyglycolic acid Drugs 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 229950009904 pritumumab Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 239000003725 proteoliposome Substances 0.000 description 1
- 108010030416 proteoliposomes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 229950011613 racotumomab Drugs 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229950011639 radretumab Drugs 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229950003238 rilotumumab Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950001808 robatumumab Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229950007308 satumomab Drugs 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 229950008684 sibrotuzumab Drugs 0.000 description 1
- 229960003323 siltuximab Drugs 0.000 description 1
- 229950009513 simtuzumab Drugs 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011267 solitomab Drugs 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229950001289 tenatumomab Drugs 0.000 description 1
- 229950010259 teprotumumab Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229950004742 tigatuzumab Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Substances CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 229950004593 ublituximab Drugs 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229950000815 veltuzumab Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- 229960004854 viral vaccine Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229950006959 vorsetuzumab Drugs 0.000 description 1
- 229950003511 votumumab Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention is directed to antibodies against human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and methods of use thereof.
Description
ANTIBODIES AGAINST CTLA-4 AND METHODS OF USE THEREOF
[0001] This application claims priority to U.S. Provisional Application No. 63/282,887, filed on November 24, 2021, the entire contents of which are incorporated herein by reference.
[0002] All patents, patent applications and publications cited herein are hereby incorporated by reference in their entirety. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.
[0003] This patent disclosure contains material that is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or the patent disclosure as it appears in the U.S. Patent and Trademark Office patent file or records, but otherwise reserves any and all copyright rights.
SEQUENCE LISTING
[0004] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on [ ], is named [ ] and is [ ] bytes in size.
FIELD OF THE INVENTION
[0005] This invention is directed to antibodies against human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and methods of use thereof.
BACKGROUND
[0006] CTLA-4 is an inhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is stronger that the affinity of their cognate stimulatory coreceptor CD28.
SUMMARY OF THE INVENTION
[0007] The invention provides for human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) and methods of use thereof.
[0008] Embodiments are drawn to an isolated antibody or fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or (b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or (c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or (d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or (e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or (I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43,
a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or (h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or (k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or (1) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or (n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID
NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or (o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or (p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or (q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or (r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or (t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or (u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ
ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481; or (v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or (w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or (x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or (z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or (aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or (bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ
ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or (cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or (dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or (ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or (gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or (hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or (ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid
sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or (jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or (kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or (11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927.
[0009] Aspects of the invention are further drawn towards an isolated scFv antibody, that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or (b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or (c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or (d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34,
a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or (e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or (I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or (h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or (j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or (k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID
NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or (1) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or (n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or (o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or (p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or (q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or (r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ
ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or (t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or (u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481 ; or (v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or (w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or (x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ
ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or (z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or (aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or (bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or (cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or (dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or (ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ
ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or (gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or (hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or (ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or (jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or (kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or (11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927.
[0010] Still further, aspects of the invention are drawn to an isolated antibody or fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain variable region comprising an amino acid sequence selected from
the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, and 1023 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 368, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, and 1024.
[0011] Also, aspects of the invention are drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, and 1023 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 368, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, and 1024.
[0012] For example, an embodiment is drawn to an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 2.
[0013] Another embodiment is drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 2.
[0014] A further embodiment is drawn to an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 3, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 4.
[0015] An embodiment is also drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 3, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 4.
[0016] An embodiment is drawn to an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA- 4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 5, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 6.
[0017] Also, embodiments are drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 5, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 6.
[0018] Still further, embodiments are drawn to an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 7, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 8.
[0019] Also, embodiments are drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 7, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 8.
[0020] Further embodiments are drawn to an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 9, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 10.
[0021] Also, embodiments are drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 9, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 10.
[0022] Embodiments are drawn to an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA- 4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 11, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 12.
[0023] Embodiments are also drawn to an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 11, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 12.
[0024] Further, embodiments are drawn towards an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 13, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 14.
[0025] Still further, embodiments are drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 13, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 14.
[0026] Also, embodiments are drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 15, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 16.
[0027] Still further, embodiments are drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 15, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 16.
[0028] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 17, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 18.
[0029] Further, embodiments are drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 17, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 18.
[0030] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 19, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 20.
[0031] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 19, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 20.
[0032] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 21, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 22.
[0033] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 21, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 22.
[0034] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 23, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 24.
[0035] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 23, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 24.
[0036] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 385, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 386.
[0037] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 385, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 386.
[0038] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 387, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 388.
[0039] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 387, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 388.
[0040] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 389, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 390.
[0041] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 389, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 390.
[0042] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 391, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 392.
[0043] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 391, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 392.
[0044] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 393, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 394.
[0045] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 393, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 394.
[0046] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 395, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 396.
[0047] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 395, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 396.
[0048] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 397, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 398.
[0049] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 397, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 398.
[0050] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 399, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 400.
[0051] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 399, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 400.
[0052] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 401, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 402.
[0053] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 401, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 402.
[0054] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 403, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 404.
[0055] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 403, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 404.
[0056] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 405, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 406.
[0057] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 405, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 406.
[0058] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 407, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 408.
[0059] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 407, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 408.
[0060] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 409, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 410.
[0061] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 409, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 410.
[0062] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 411, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 412.
[0063] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 411, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 412.
[0064] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1001, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1002.
[0065] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1001, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1002.
[0066] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1003, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1004.
[0067] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1003, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1004.
[0068] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1005,
and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1006.
[0069] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1005, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1006.
[0070] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1007, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1008.
[0071] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1007, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1008.
[0072] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1009, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1010.
[0073] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1009, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1010.
[0074] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1011, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1012.
[0075] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1011, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1012.
[0076] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1013, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1014.
[0077] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1013, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1014.
[0078] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1015, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1016.
[0079] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid
sequence about 95% identical to SEQ ID NO: 1015, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1016.
[0080] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1017, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1018.
[0081] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1017, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1018.
[0082] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1019, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1020.
[0083] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1019, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1020.
[0084] Embodiments are also drawn towards n isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1021, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1022.
[0085] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1021, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1022.
[0086] Embodiments are also drawn towards an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1023, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1024.
[0087] Embodiments are also drawn towards an isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1023, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1024.
[0088] Aspects of the invention are also drawn towards an isolated monoclonal antibody or antigen-binding fragment of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, or 79, wherein the isolated monoclonal antibody or antigen-binding fragment comprises a wildtype Fc or a modified Fc.
[0089] Further, aspects of the invention are drawn to an isolated bispecific antibody comprising an antibody or fragment as described herein, and a second antigenbinding fragment having specificity to a molecule on an immune cell. For example, the molecule is selected from the group consisting of CCR4, B7H3, B7H4, CD27, CD28, CD40, CD40L, CD47, CD122, CTLA-4, GITR, GITRL, ICOS, ICOSL, LAG-3, LIGHT, OX-40, OX40L, PD-1, TIM3, 4-1BB, TIGIT, VISTA, HEVM, BTLA, CD47, PDL1, MICA, MICB, and KIR.
[0090] In embodiments, the fragment and the second fragment each is independently selected from a Fab fragment, a single-chain variable fragment (scFv), or a single-domain antibody.
[0091] Embodiments can further comprise a Fc fragment. For example, the Fc fragment comprises a wildtype Fc fragment or a modified Fc fragment.
[0092] Aspects of the invention are drawn towards a nucleic acid encoding an antibody as described herein.
[0093] Still further, aspects of the invention are drawn towards a nucleic acid encoding a bispecific antibody as described herein.
[0094] Also, aspects of the invention are drawn towards a pharmaceutical composition comprising the antibody or fragment thereof as described herein, and a pharmaceutically acceptable carrier or excipient.
[0095] Embodiments can further comprise at least one additional therapeutic agent. For example, the therapeutic agent can be a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
[0096] Aspects of the invention are drawn to a pharmaceutical composition comprising the bispecific antibody as described herein, and a pharmaceutically acceptable carrier or excipient.
[0097] In embodiments, the pharmaceutical composition can further comprise at least one additional therapeutic agent. For example, the therapeutic agent can be a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
[0098] Further, aspects of the invention are drawn to an isolated cell comprising one or more polynucleotide(s) encoding an antibody or fragment as described herein.
[0099] Also, aspects of the invention are drawn towards an isolated cell comprising one or more polynucleotide(s) encoding a bispecific antibody or fragment thereof as described herein.
[00100] Further, aspects of the invention are drawn towards a vector comprising a nucleic acid as described herein.
[00101] Also, aspects of the invention are drawn to a cell comprising a vector as described herein.
[00102] Aspects of the invention are drawn to methods of treating a cancer in a subject. For example, the method comprises administering to a subject a therapeutically effective amount of the CTLA-4 antibody or fragment thereof as described herein. For example, the method comprises administering to a subject a therapeutically effective amount of a CTLA-4 bispecific antibody as described herein.
[00103] Aspects of the invention are also drawn towards a chimeric antigen receptor (CAR). In embodiments, the CAR comprises an intracellular signaling domain, a transmembrane domain and an extracellular domain, wherein the extracellular domain is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), wherein the monoclonal antibody or fragment thereof comprises a heavy chain, light chain, or combination thereof, wherein the heavy chain comprises (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or (b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or (c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or (d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or (e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino
acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or (I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or (h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or (k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or (1) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino
acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or (n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or (o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or (p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or (q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or (r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising
the amino acid sequence of SEQ ID NO: 475; or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or (u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481 ; or (v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or (w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or (x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or (z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or (aa) a VH CDR1
comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or (bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or (cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or (dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or (ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or (gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or (hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2
comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or (ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or (jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or (kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or (11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927. For example, the transmembrane domain comprises CD28.
[00104] In embodiments, the transmembrane domain further comprises a stalk region positioned between the extracellular domain and the transmembrane domain.
[00105] Embodiments can further comprise one or more additional costimulatory molecules positioned between the transmembrane domain and the intracellular signaling domain. For example, the costimulatory molecules is CD28, 4-1BB, ICOS, or 0X40. For example, the intracellular signaling domain comprises a CD3 zeta chain.
[00106] In embodiments, the antibody is a Fab or a scFV.
[00107] Aspects of the invention are also drawn to a nucleic acid encoding a CAR as described herein. In embodiments, the nucleic acid can further comprise a nucleic acid encoding a polypeptide positioned after the intracellular signaling domain. For example, the polypeptide is an antibody or a cytokine, such as an scFV.
[00108] Aspescts of the invention are drawn towards a nucleic acid encoding a CAR, wherein the CAR comprises an intracellular signaling domain, a transmembrane domain and an extracellular domain, further comprising a nucleic acid encoding a polypeptide positioned after the intracellular signaling domain, wherein the polypeptide comprises an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T- Lymphocyte Associated Protein 4 (CTLA-4), wherein the monoclonal antibody or fragment thereof comprises a heavy chain, light chain, or combination thereof, wherein the heavy chain comprises (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or (b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or (c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or (d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or (e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID
NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or (I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or (h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or (j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or (k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or (1) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ
ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or (n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or (o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or (p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or (q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or (r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of
SEQ ID NO: 475; or (t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or (u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481 ; or (v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or (w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or (x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or (z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or (aa) a VH CDR1 comprising the amino acid
sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or (bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or (cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or (dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or (ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or (gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or (hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino
acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or (ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or (jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or (kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or (11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927..
[00109] Aspects of the invention are drawn towards a vector comprising the nucleic acid as describd herein.
[00110] Aspects of the invention are also drawn to a cell comprising a vector as described herein.
[00111] Aspects of the invention are drawn towards a genetically engineered cell which expresses and bears on the cell surface membrane a chimeric antigen receptor as described herein. For example, the cell is a T-cell or an NK cell. For example, the T cell is CD4+ or CD8+.
[00112] Embodiments can further comprise a mixed population of CD4+ and CD8 cells+.
[00113] Aspects of the invention are also drawn towards a genetically engineered cell which express and bear on the cell surface membrane a chimeric antigen receptor, and which is further engineered to express and secrete a polypeptide, wherein polypeptide is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T- Lymphocyte Associated Protein 4 (CTLA-4), wherein the monoclonal antibody or fragment thereof comprises a heavy chain, light chain, or combination thereof, wherein the heavy chain comprises (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or (b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or (c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or (d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or (e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or (I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ
ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or (g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or (h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or (j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or (k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or (1) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or (m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID
NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or (n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or (o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or (p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or (q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or (r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or (t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ
ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or (u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481 ; or (v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or (w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or (x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or (z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or (aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of
SEQ ID NO: 894; or (bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or (cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or (dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or (ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or (gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or (hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or (ii) a VH CDR1 comprising the
amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or (jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or (kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or (11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927.
[00114] Other objects and advantages of this invention are readily apparent from the ensuing description.
BRIEF DESCRIPTION OF THE FIGURES
[00115] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[00116] FIG. 1 shows binding ELISA with PEG purified phage at varying dilutions.
[00117] FIG. 2 shows FACS confirms CTLA-4 phages can bind to CTLA-4-expressing
1G5 Jurkat cells.
[00118] FIG. 3 provides anti-CTLA-4 antibody amino acid (AA) and nucleotide (Nuc) sequences. “HC” is heavy chain, and “LC” is light chain.
[00119] FIG. 4 - FIG. 8 provides anti-CTLA-4 antibody amino acid (AA) and nucleotide (Nuc) sequences.
[00120] FIG. 9 - FIG. 11 provides anti-CTLA-4 antibody amino acid (AA) and nucleotide (Nuc) sequences.
[00121] FIG. 12 shows percent competition with CD80 hFc for binding to CTLA4 on 1G5 Jurkat. 1G5 Jurkat cells were transduced to overexpress CTLA4. Cells were incubated with soluble antibody at the indicated concentration, washed, then incubated with labeled CD80- Fc. Samples were read on a BD FACSCanto II. Decrease in fluorescence was used to indicate blockade of CD80 binding to the CTLA4 on the surface of the cells.
[00122] FIG. 13 shows a ribbon diagram adapted from Metzler, William J., et al. “Solution Structure of Human CTLA-4 and Delineation of a CD80/CD86 Binding Site Conserved in CD28.”
[00123] FIG. 14 shows ribbon diagrams adapted from Stamper, Carin C., et al. “Crystal Structure of the B7-1/CTLA-4 Complex That Inhibits Human Immune Responses.” Nature.
[00124] FIG. 15 shows schematics of mechanisms to suppress immune response.
[00125] FIG. 16 shows ribbon diagrams of existing therapies: Ipilimumab- IgGl and Tremelimumab- IgG2. Panels A and B show ribbon diagrams adapted from Ramagopal, Udupi A., et al. “Structural Basis for Cancer Immunotherapy by the First-in-Class Checkpoint Inhibitor Ipilimumab.” Panel C shows a ribbon diagram adapted from He, Mengnan, et al. “Remarkably Similar CTLA-4 Binding Properties of Therapeutic Ipilimumab and Tremelimumab Antibodies.”
[00126] FIG. 17 shows a chart of exemplary panning results for anti-CTLA4 antibodies. Rounds: 1, lb, 2, 2b, 3, 3b. Mouse CTLA4 were introduced in rounds 3 and 3b. 10 unique antibodies were the result.
[00127] FIG. 18 shows a chart of exemplary kinetic analysis of aCTLA4 antibodies.
[00128] FIG. 19 shows a chart of exemplary competition analysis of aCTLA4 antibodies.
[00129] FIG. 20 shows a graph of FACS of aCTLA4 antibodies binding to T cells. E1-D7 binds significantly more CTLA4 on T cells compared to T2-C10. An anti-CTLA4 ab from biolegend was used at a single point (recommended staining cone) for the control. Ipi IgG is an antibody cloned in the lab to represent ipilimumab, it is not a commercial prep or biosimilar.
[00130] FIG. 21 shows exemplary FACS of aCTLA4 Abs binding to T Cells.
[00131] FIG. 22 shows exemplary graphs of ELISA results of mouse/human CTLA4 cross reactivity. E1-D7 cross reacts with mouse CTLA4.
[00132] FIG. 23 shows a schematic of exemplary mechanisms of T cells adapted from P. Ott et al. 2014.
[00133] FIG. 24 shows a schematic of an MLR assay. Schematic courtesy of Explicyte. Protocol: Co-culture of CD4+ T cells with monocyte-derived DCs each from different donors. This indicated allorecognition of the dendritic cells leads to activation of T cells. DCs expressing PDL1 can suppress T cell activation. Addition of immune checkpoint inhibitors can recover T cell from suppression. We investigated whether anti-PDl enhances T cell activation. Measured IFNy and IL2 cytokine production, indicators of T cell activation.
[00134] FIG. 25 shows data from immunophenotyping of monocytes, imMo-DCs, and mMo-DCs adapted from Miltenyi. In this protocol Isolate CD14+ monocytes using Miltenyi CD 14+ microbeads were cultured in Miltenyi Mo-DC media (pre-prepared media with GM- CSF + IL4) and cultured for 5 days. Then, TNF-a (1000 U/ml), IL-ip (5 ng/ml), IL-6 (10 ng/ml) and prostaglandin E2 (PGE2) (1 pM) was added and cultured for 2 days to mature DC. mMo-DCs express various DC markers that are involved in the formation of immunological synapses between DCs and naive T cells, including CD80, CD86, and MHC II (HLA-DR). Mature Mo-DCs also expressed DC activation markers CD83, CD40, and CCR7.
[00135] FIG. 26 shows data and analysis of DC donor AD staining.
[00136] FIG. 27 shows graphs of exemplary MLR1 data: measuring IFNy production. We investigated if E1-D7 suppressed T cell activation. A decrease in IFNy is seen in wells treated
with E1-D7 compared to T cells + DC only, anti-PDl treatment, and irrelevant Ab control.
An absorbance value of 4 was used to represent saturation.
[00137] FIG. 28 shows graphs of exemplary data of the combination of aCTLA4/aPD-l MLR: IFNy production.
[00138] FIG. 29 shows an exemplary schematic of the second panning using CTLA4- PMPLs.
[00139] FIG. 30 shows exemplary graphs of data from binding ELISA with PEG purified phage at varying dilutions.
[00140] FIG. 31 shows exemplary FACS confirming our CTLA4 phages can bind to CTLA-4 expressing 1G5 Jurkat cells.
[00141] FIG. 32 shows a chart of exemplary kinetic screening data of aCTLA4 scFv-Fc sup.
[00142] FIG. 33 shows an exemplary binding curve for hCTLA4.
[00143] FIG. 34 shows an exemplary binding curve for mCTLA4.
[00144] FIG. 35 shows a BSA negative control binding curve.
[00145] FIG. 36 shows a chart of data and observations. The data is arranged in decreasing order of Association response at 25nM concentration of antibodies. All candidate antibodies have higher dissociation rates than Ipilimumab and BiolegendaCTLA4 (commercial controls). Most candidates seem to have a higher association response than the commercial controls. 4 candidates (highlighted in the table) have lower dissociation constants than E1-D7 (Taylor’s Antibody - Lab Control). E2-D10 and E1-A12 have identical heavy chains but have different families of light chains. The difference in their response rates is mediated by light chain binding. E2-H10 also belongs to the same Vh family as the two above.
[00146] FIG. 37 shows a chart of exemplary data from a competition assay. CD80 blockade: All candidate antibodies block CD80 binding to some extent, but none more than Ipilimumab, so I selected for candidates that have higher blockade (lower values of second association) than E1-D7 (lab control, Taylor’s candidate). CD86 blockade: All candidates have negative values of second association, signaling they all block CD86 completely
(normalized values = 0). I selected for candidates that have negative values closer to zero when compared to Ipilimumab because higher negative values could indicate antibody dissociation. E1-A8 and E2-A4 belong to the same germline family. E1-D7 blockade: Highlighted candidates block E1-D7 binding better than Ipilimumab. Ipilimumab blockade: Highlighted candidates block Ipilimumab binding better than E1-D7. All candidates that block CD80 and CD86 performed relatively poorly in Kinetics.
[00147] FIG. 38 shows an exemplary graph of CTLA4 binding. Jurkat cells were transduced with hCTLA4 and used to generate a binding curve.
[00148] FIG. 39 shows a schematic of a PROMEGA lucierfase reporter assay adapted from www. moleculardevices . com/ en/ assets/ app-note/br/ characterize-biologics-for-immune- checkpoint-blockade-with-reporter-bioassays-using-spectramax-microplate-readers#gref.
[00149] FIG. 40 shows graphs of exemplary Promega CTLA4 bioassay data. Anti-CTLA4 scFv-Fcs were tested against an Ipi biosimilar IgG. Plates were read using a BMG polarstar omega with an interval of either 1 second (left column) or 10 seconds (right column). El- B10, E1-A8, E2-A4, and E1-D7 show similar activity at about 40% of Ipi. On plate 2, E2-G9 shows comparable activity to ipi however E2-H10, E1-A4, and E2-H12 show minimal improvement.
[00150] FIG. 41 shows an illustration of a bispecific design. BsAbs constructed with the IgGl hinge show a mix of monomer and dimer when expressed so to increase dimerization frequency we switched to an IgG3 hinge. We initially built two constructs, one with a (G4S)5 linker preceding the IgG3 hinge and one without the leading linker. The second linker was maintained at 5 repeats to provide ample space for the 2nd scFv to reach binding sites without interference from the hinge.
[00151] FIG. 42 shows sequences of IgG3 hinge linker sequences.
[00152] FIG. 43 shows a picture of an exemplary labeled SDS Page Gel for Non-reduced and Reduced ElD7-IgG3 hinge-P4B3M3 and P4B3M3-IgG3 hinge-E!D7 bsAbs.
[00153] FIG. 44 shows a chart of exemplary data. SA sensors were loaded with biotinylated CTLA4 or PD1 and the indicated abs were allowed to associate/disassociate. Due to sensor drift, the off rates of the PD1 loaded sensors are unreliable.
[00154] FIG. 45 shows data from exemplary dual binding assays. CTLA4+, PD1+, or CTLA4+PD1+ Jurkat cells were first coated with the indicated amount of mono or bispecific protein. Soluble protein was next added and allowed to bind to free arms. As shown here, monospecific abs are not able to bind significant amounts of soluble antigen, however when bound to PD1 expressing cells, the bsAbs are able to capture soluble CTLA4 from solution.
[00155] FIG. 46 shows non-limiting, exemplary data from a competition assay for Ab (including combination mAbs) vs CD80 hFc for CTLA4+/PD1+ 1G5 Jurkat. BsAb demonstrates remarkably improved competition of CD80 binding to PD1+CTLA4+ jurkat cells when compared to a monospecific antibody and a cocktail.
[00156] FIG. 47 shows non-limiting, exemplary data from a % competition assay with CD80 hFc for binding to CTLA4 on 1G5 Jurkat. CD80 competition assay using CTLA4 transduced Jurkat cells: Four bispecific constructs were tested for CD80 competition. Two had the full 5,5 linker configuration and two had the abbreviated 0,5 linker. We also switched the order of the aPDl/aCTLA4 abs in the final construct. As shown here, E1-D7 and El- D7+P4B3m3 combination therapy leads to moderate competition, however the creation of the bsAb shows a pronounced increase in CD80 competition, likely due to the additional binding potential generated by the anti-PDl domain.
[00157] FIG. 48 shows photos and illustrations of clear cell renal cell carcinoma panel (A) characteristics (adapted from Li et al, 2019), panel (B) model for cellular differentiation (adapted from Tun et.al, 2010), and panel (C) epidemiology (adapted from Hsieh et al, 2019).
[00158] FIG. 49 shows a graph of OS of ccRCC patients adapted from Feng et al., 2019.
[00159] FIG. 50 shows graphs of the representation of immune populations of ccRCC adapted from Chevrier et al., 2017.
[00160] FIG. 51 shows illustrations and graphs of the CTLA4 signaling pathway. Panel A shows an illustration of the CTLA4 signalling pathway. Panel B shows a graph CTLA4 overexpression in ccRCC (adapted from Lie et al, 2020). Panel C shows an illustration of Ipilimumab and CTLA4 blockade.
[00161] FIG. 52 shows pictures and illustrations of the PD1 signalling pathway adapted from Kim et al., 2021. Panel A shows the PD1-PDL1 signalling pathway. Panel B shows
histology images of PD1 overexpression in ccRCC. Panel C shows an illustration of PD1 blockage and non-limiting effects.
[00162] FIG. 53 shows illustrations of dual checkpoint blockade by bispecific antibodies. Panel A shows a schematic dual CTLA4/PDL checkpoint blockade. Panel B shows nonlimiting, exemplary bispecific antibody formats.
[00163] FIG. 54 shows a table of exemplary anti-CTLA4/antiPDl bispecifics used in the clinic.
[00164] FIG. 55 shows a schematic of a non-limiting, exemplary experimental design to evaluate the binding affinity of anti-CTLA4 candidates to human and mouse CTLA4 at various concentrations using ELISA.
[00165] FIG. 56 shows non-limiting data and results of ELISA binding curve. Panel A shows ELISA binding curve to indicate binding affinity of anti-CTLA4 candidates to hCTLA4. Panel B shows ELISA binding curve to indicate binding affinity of anti-CTLA4 candidates to mCTLA4. Panel C shows ELISA binding curve to indicate binding affinity of anti-CTLA4 candidates to BSA (negative control).
[00166] FIG. 57 shows a non-limiting, exemplary experimental design to characterize the kinetic properties of the antibody candidates using BLI-Octet.
[00167] FIG. 58 shows non-limiting, data indicating the kinetic properties of anti-CTLA4 candidates. All tested candidates have higher dissociation rates when compared to Ipilimumab, even when they have a higher association response. Among the candidates, C, B, and G appear to have the lowest dissociation rates. KD - Dissociation constant, Kon - Rate of association, Kon - Rate of association.
[00168] FIG. 59 shows a schematic of a non-limiting, exemplary experimental design to determine the ability of anti-CTLA4 antibodies to block CD80/CD86/Ipilimumab binding and determine the similarity in the localization of antibodies and ligands on the surface of CTLA4.
[00169] FIG. 60 shows a chart of the percentage blockade of CD80/CD86/Ipilimumab binding to CTLA4 by anti-CTLA4 candidates. CD80: Ipilimumab blocks CD80 to the highest extent. The candidates that show the highest CD80 blockade: I, E, J. CD86: All
candidates show 100% blockade of CD86 binding. This could be due to documented lower affinity of CD86 binding to CTLA4. Ipilimumab: All candidates block the binding of Ipilimumab to CTLA4 to some extent, even those that cross-react with mCTLA4.
[00170] FIG. 61 shows ribbon diagrams Ipilimumab complexes adapted from He M, Chai Y, Qi J, Zhang CWH, Tong Z, Shi Y, Yan J, Tan S, Gao GF. Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget. 2017 May 19;8(40):67129-67139. doi: 10.18632/oncotarget.18004. PMID: 28978021; PMCID: PMC5620161. Panel A shows Ipilimumab complexed with hCTLA4 - Contact residues highlighted. Panel B shows Ipilimumab complexed with mCTLA4 - Aligned epitope highlighted.
[00171] FIG. 62 shows ribbon diagrams of CD80 complexes adapted from Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, Stahl ML, Seehra J, Somers WS, Mosyak L. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001 Mar 29;410(6828):608-l l. doi: 10.1038/35069118. Erratum in: Nature 2001 May 31 ;411(6837):617. PMID: 11279502. Panel A shows CD80 complexed with hCTLA4 - Contact residues highlighted. Panel B shows CD 80 complexed with mCTLA4 - Aligned epitope highlighted.
[00172] FIG. 63 shows a non-limiting, exemplary schematic of an experimental design to determine the binding affinity of the candidate antibodies to Jurkat cells that express CTLA4.
[00173] FIG. 64 shows a non-limiting, exemplary binding curve of the binding affinity of anti-CTLA4 candidates to CTLA4+ Jurkat cells.
[00174] FIG. 65 shows a non-limiting, exemplary schematic of an experimental design to assess the biological significance of antibody binding in facilitating CD28 signalling.
[00175] FIG. 66 shows non-limiting, exemplary graphs of fold induction of Luciferase vs. concentration of anti-CTLA4 candidates. Across both plates, Ipilimumab shows the highest induction of Luciferase expression. Five of the 8 tested candidates: E, H, J, F, and I, show a similar response.
[00176] FIG. 67 shows anti-CTLA-4 antibody germline alignment.
[00177] FIG. 68 shows anti-CTLA-4 antibody amino acid sequences.
[00178] FIG. 69 shows anti-CTLA-4 antibody nucleic acid sequences.
DETAILED DESCRIPTION
[00179] Abbreviations and Definitions
[00180] Detailed descriptions of one or more embodiments are provided herein. It is to be understood, however, that the present invention may be embodied in various forms.
Therefore, specific details disclosed herein are not to be interpreted as limiting, but rather as a basis for the claims and as a representative basis for teaching one skilled in the art to employ the present invention in any appropriate manner.
[00181] The singular forms “a”, “an” and “the” include plural reference unless the context clearly dictates otherwise. The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
[00182] Wherever any of the phrases “for example,” “such as,” “including” and the like are used herein, the phrase “and without limitation” is understood to follow unless explicitly stated otherwise. Similarly, “an example,” “exemplary” and the like are understood to be nonlimiting.
[00183] The term “substantially” allows for deviations from the descriptor that do not negatively impact the intended purpose. Descriptive terms are understood to be modified by the term “substantially” even if the word “substantially” is not explicitly recited.
[00184] The terms “comprising” and “including” and “having” and “involving” (and similarly “comprises”, “includes,” “has,” and “involves”) and the like are used interchangeably and have the same meaning. Specifically, each of the terms is defined consistent with the common United States patent law definition of “comprising” and is therefore interpreted to be an open term meaning “at least the following,” and is also interpreted not to exclude additional features, limitations, aspects, etc. Thus, for example, “a process involving steps a, b, and c” means that the process includes at least steps a, b and c. Wherever the terms “a” or “an” are used, “one or more” is understood, unless such interpretation is nonsensical in context.
[00185] The term “about” is used herein to mean approximately, roughly, around, or in the region of. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In
general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20 percent up or down (higher or lower).
[00186] CTLA-4
[00187] Human antibody-phage screens were performed against human CTLA-4 (rounds 1- 3) or muring CTLA-4 (Round 3). The first set of antibodies was discovered via panning against the soluble protein, and the second set was discovered by PMPL panning.
[00188] The binding activity have been characterized for a panel of human monoclonal antibodies against human CTLA-4. Anti-CTLA-4 immunotherapy is being evaluated as part of the burgeoning field of ImmunoOncology. The anti-CTLA-4 mAbs described herein can have therapeutic potential. CTLA-4 antibodies have been identified with varying affinity towards CTLA-4.
[00189] Aspects of the invention provide isolated antibodies specific against CTLA-4. The term “isolated” as used herein with respect to cells, nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source of the macromolecule. The term “isolated” can also refer to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. For example, an “isolated nucleic acid” can include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. “Isolated” can also refer to cells or polypeptides which are isolated from other cellular proteins or tissues. Isolated polypeptides can include both purified and recombinant polypeptides. The isolated antibodies were identified through the use of a 27 billion member human single-chain antibody (scFv) phage library panned against soluble or paramagnetic proteoliposomes displayed CTLA4 as the selection target. These antibodies represent a new class of monoclonal antibodies against CTLA-4. The monoclonal CTLA-4 antibodies discussed herein can also be used in the construction of multi-specific antibodies or as the payload for a genetically engineered cell, such as a CAR-T cell, a CAR-NK cell, or a genetically engineered B cell.
[00190] Unique recombinant monoclonal CTLA-4 antibodies are described herein. “Recombinant” as it pertains to polypeptides (such as antibodies) or polynucleotides refers to a form of the polypeptide or polynucleotide that does not exist naturally, a non-limiting
example of which can be created by combining polynucleotides or polypeptides that would not normally occur together.
[00191] The amino acid sequence of the monoclonal CTLA-4 antibodies are provided herein (see Tables 1-26); the amino acid sequences of the heavy and light chain complementary determining regions CDRs of the CTLA-4 antibodies are underlined (CDR1). underlined and bolded (CDR2). or underlined, italiciz.ed, and bolded (CDR3) below:
[00192] The nucleic acid sequence of the monoclonal CTLA-4 antibodies are provided herein (see Tables 27-52):
[00193] The amino acid sequences of the heavy and light chain complementary determining regions of the CTLA-4 antibodies are shown in Table 53A-B below:
Table 53A. Heavy chain (VH) complementary determining regions (CDRs) of the CTLA-4 antibodies
Table 53B. Light chain (VL) complementary determining regions (CDRs) of the CTLA-4 antibodies
[00194] The nucleic acid sequences of the heavy and light chain complementary determining regions of the CTLA-4 antibodies are shown in Table 54A-B below:
Table 54A. Heavy chain (VH) complementary determining regions (CDRs) of the CTLA-4 antibodies
Table 54B. Light chain (VL) complementary determining regions (CDRs) of the CTLA-4 antibodies
[00195] The amino acid sequences of the heavy and light chain framework regions of the
CTLA4 antibodies are shown in Table 55A-B below:
Table 55A. Heavy chain (VH) framework regions (FRs) of the CTLA-4 antibodies
Table 55B. Light chain (VL) framework regions (FRs) of the CTLA-4 antibodies
[00196] The nucleic acid sequences of the heavy and light chain framework regions of the
CTLA-4 antibodies are shown in Table 56A-B below:
Table 56A. Heavy chain (VH) framework regions (FRs) of the CTLA-4 antibodies
Table 56B. Light chain (VL) framework regions (FRs) of the CTLA-4 antibodies
[00197] The CTLA-4 antibodies described herein bind to CTLA-4. In one embodiment, the CTLA-4 antibodies have high affinity and high specificity for CTLA-4. Some embodiments also feature antibodies that have a specified percentage identity or similarity to the amino acid or nucleotide sequences of the anti- CTLA-4 antibodies described herein. For example, “homology” or “identity” or “similarity” refers to sequence similarity between two peptides or between two nucleic acid molecules. Homology can be determined by comparing a
position in each sequence, which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree of homology between sequences is a function of the number of matching or homologous positions shared by the sequences. For example, the antibodies can have 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher amino acid sequence identity when compared to a specified region or the full length of any one of the anti-CTLA-4 antibodies described herein. For example, the antibodies can have 60%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher nucleic acid identity when compared to a specified region or the full length of any one of the anti-CTLA-4 antibodies described herein. Sequence identity or similarity to the nucleic acids and proteins of the present invention can be determined by sequence comparison and/or alignment by methods known in the art, for example, using software programs known in the art, such as those described in Ausubel et al. eds. (2007) Current Protocols in Molecular Biology. For example, sequence comparison algorithms (i.e. BLAST or BLAST 2.0), manual alignment or visual inspection can be utilized to determine percent sequence identity or similarity for the nucleic acids and proteins of the present invention.
[00198] “Polypeptide” as used herein can encompass a singular “polypeptide” as well as plural “polypeptides,” and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term “polypeptide” refers to any chain or chains of two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, “protein,” “amino acid chain,” or any other term used to refer to a chain or chains of two or more amino acids, can refer to “polypeptide” herein, and the term “polypeptide” can be used instead of, or interchangeably with any of these terms. “Polypeptide” can also refer to the products of post-expression modifications of the polypeptide, including without limitation glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids. A polypeptide can be derived from a natural biological source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It may be generated in any manner, including by chemical synthesis. As to amino acid sequences, one of skill in the art will readily recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, deletes, or substitutes a single amino acid or a small percentage of amino acids in the encoded sequence is collectively
referred to herein as a "conservatively modified variant". In some embodiments the alteration results in the substitution of an amino acid with a chemically similar amino acid.
Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants of the anti-CTLA-4 antibodies disclosed herein can exhibit increased cross-reactivity to CTLA-4 in comparison to an unmodified CTLA-4 antibody.
[00199] For example, a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a nonessential amino acid residue in an immunoglobulin polypeptide is replaced with another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced with a structurally similar string that differs in order and/or composition of side chain family members.
[00200] Antibodies
[00201] As used herein, an “antibody” or “antigen-binding polypeptide” can refer to a polypeptide or a polypeptide complex that specifically recognizes and binds to an antigen. An antibody can be a whole antibody and any antigen binding fragment or a single chain thereof. For example, “antibody” can include any protein or peptide containing molecule that comprises at least a portion of an immunoglobulin molecule having biological activity of binding to the antigen. Non-limiting examples a complementarity determining region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a framework (FR) region, or any portion thereof, or at least one portion of a binding protein. As used herein, the term "antibody" can refer to an immunoglobulin molecule and immunologically active portions of an immunoglobulin (Ig) molecule, i.e., a molecule that contains an antigen binding site that specifically binds (immunoreacts with) an antigen. By "specifically binds" or "immunoreacts with" is meant that the antibody reacts with one or more antigenic determinants of the desired antigen and does not react with other polypeptides.
[00202] The terms “antibody fragment” or “antigen-binding fragment”, as used herein, is a portion of an antibody such as F(ab’)2, F(ab)2, Fab', Fab, Fv, scFv and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. The term “antibody fragment” can include aptamers (such as spiegelmers), minibodies, and diabodies. The term “antibody fragment” can also include any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex. Antibodies, antigen-binding polypeptides, variants, or derivatives described herein include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, epitope-binding fragments, e.g., Fab, Fab' and F(ab')2, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies, dAb (domain antibody), minibodies, disulfide-linked Fvs (sdFv), fragments comprising either a VL or VH domain, fragments produced by a Fab expression library, and anti-idiotypic (anti-Id) antibodies.
[00203] A “single-chain variable fragment” or “scFv” refers to a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of immunoglobulins. A single chain Fv ("scFv") polypeptide molecule is a covalently linked VH:VL heterodimer, which can be expressed from a gene fusion including VH- and VL-encoding genes linked by a peptide- encoding linker. (See Huston et al. (1988) Proc Nat Acad Sci USA 85(16):5879-5883). In some aspects, the regions are connected with a short linker peptide of ten to about 25 amino acids. The linker can be rich in glycine for flexibility, as well as serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the original immunoglobulin, despite removal of the constant regions and the introduction of the linker. A number of methods have been described to discern chemical structures for converting the naturally aggregated, but chemically separated, light and heavy polypeptide chains from an antibody V region into an scFv molecule, which will fold into a three dimensional structure substantially similar to the structure of an antigen-binding site. See, e.g., U.S. Patent No. 5,091,5 13; No. 5,892,019; No. 5,132,405; and No. 4,946,778, each of which are incorporated by reference in their entireties.
[00204] Very large naive human scFv libraries have been and can be created to offer a large source of rearranged antibody genes against a plethora of target molecules. Smaller libraries can be constructed from individuals with infectious diseases in order to isolate diseasespecific antibodies. (See Barbas et al., Proc. Natl. Acad. Sci. USA 89:9339-43 (1992); Zebedee et al, Proc. Natl. Acad. Sci. USA 89:3 175-79 (1992)).
[00205] Antibodies of the invention can also be modified to produce mosaic antibodies. A mosaic antibody is one in which the external amino acid residues of an antibody of one species are rationally replaced or "mosaicked" by the external amino acid residues of an antibody of a second species such that the antibody of the first species is not immunogenic in the second species, thereby reducing the immunogenicity of the antibody. Since the antigenicity of a protein depends primarily on its surface properties, the immunogenicity of an antibody can be reduced by substituting exposed residues that differ from those typically found in antibodies of another mammalian species. Reasonable substitution of this external residue should have little or no effect on the internal domain or on inter-domain contacts. Thus, since the changes are limited to variable region framework residues, ligand binding properties should not be affected. This process is called "mosaicism" since only the outer surface or skin of the antibody is altered and the supporting residues remain undisturbed.
[00206] The "mosaicing" process utilizes sequence data for human antibody variable domains compiled by available Kabat et al (1987) Sequences of Proteins of Immunological interest, 4th ed., Bethesda, Md., National Institutes of Health, updates to this database, and other accessible U.S. and foreign databases (nucleic acids and Proteins). Non-limiting examples of methods for generating mosaic antibodies include EP 519596; U.S. Pat. No. 6,797,492; and is described in Padlan et al, 1991.
[00207] Antibody molecules obtained from humans fall into five classes of immunoglobulins: IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (y, p, a, 6, s) with some subclasses among them (e.g., yl-y4). Certain classes have subclasses as well, such as IgGi, IgG2, IgGi and IgGi and others. The immunoglobulin subclasses (isotypes) e.g., IgGi, IgG2, IgGi, IgGi, IgGs, etc. are well characterized and are known to confer functional specialization. With regard to IgG, a standard immunoglobulin molecule comprises two identical light chain polypeptides of molecular weight approximately 23,000 Daltons, and two identical heavy chain polypeptides of molecular weight 53,000-70,000. The four chains are typically joined by disulfide bonds in a “Y” configuration wherein the light chains bracket the heavy chains starting at the mouth of the “Y” and continuing through the variable region. Immunoglobulin or antibody molecules described herein can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGi, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of an immunoglobulin molecule.
[00208] Light chains are classified as either kappa or lambda (K, Z). Each heavy chain class can be bound with either a kappa or lambda light chain. In general, the light and heavy chains are covalently bonded to each other, and the “tail” portions of the two heavy chains are bonded to each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells, or genetically engineered host cells. In the heavy chain, the amino acid sequences run from an N-terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each chain.
[00209] Both the light and heavy chains are divided into regions of structural and functional homology. The terms “constant” and “variable” are used functionally. The variable domains of both the light (VL) and heavy (VH) chain portions determine antigen recognition and specificity. Conversely, the constant domains of the light chain (CL) and the heavy chain (CHI, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. The term "antigen-binding site," or "binding portion" can refer to the part of the immunoglobulin molecule that participates in antigen binding. The antigen binding site is formed by amino acid residues of the N-terminal variable ("V") regions of the heavy ("H") and light ("L") chains. Three highly divergent stretches within the V regions of the heavy and light chains, referred to as "hypervariable regions," are interposed between more conserved flanking stretches known as "framework regions," or "FRs". Thus, the term "FR" can refer to amino acid sequences which are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three dimensional space to form an antigen-binding surface. The antigen-binding surface is complementary to the three-dimensional surface of a bound antigen, and the three hypervariable regions of each of the heavy and light chains are referred to as "complementarity -determining regions," or "CDRs." VH and VL regions, which contain the CDRs, as well as frameworks (FRs) of the CTLA-4 antibodies are shown in Table lA-Table 12B.
[00210] The six CDRs present in each antigen-binding domain are short, non-contiguous sequences of amino acids that are specifically positioned to form the antigen-binding domain as the antibody assumes its three dimensional configuration in an aqueous environment. The remainder of the amino acids in the antigen-binding domains, the FR regions, show less inter- molecular variability. The framework regions largely adopt a [3-sheet conformation and the CDRs form loops which connect, and in some cases form part of, the [3-sheet structure. The
framework regions act to form a scaffold that provides for positioning the CDRs in correct orientation by inter-chain, non-covalent interactions. The antigen-binding domain formed by the positioned CDRs provides a surface complementary to the epitope on the immunoreactive antigen, which promotes the non-covalent binding of the antibody to its cognate epitope. The amino acids comprising the CDRs and the framework regions, respectively, can be readily identified for a heavy or light chain variable region by one of ordinary skill in the art, since they have been previously defined (See, “Sequences of Proteins of Immunological Interest,” Kabat, E., et al., U.S. Department of Health and Human Services, (1983); and Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987)).
[00211] Where there are two or more definitions of a term which is used and/or accepted within the art, the definition of the term as used herein is intended to include all such meanings unless explicitly stated to the contrary. A specific example is the use of the term “complementarity determining region” (“CDR”) to describe the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. This particular region has been described by Kabat et al., U.S. Dept, of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983) and by Chothia et al., J. Mol. Biol. 196:901-917 (1987), which are incorporated herein by reference in their entireties. The CDR definitions according to Kabat and Chothia include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope of the term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth in the table below as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those skilled in the art can routinely determine which residues comprise a particular CDR given the variable region amino acid sequence of the antibody.
[00212] Kabat et al. defined a numbering system for variable domain sequences that is applicable to any antibody. The skilled artisan can unambiguously assign this system of “Kabat numbering” to any variable domain sequence, without reliance on any experimental data beyond the sequence itself. As used herein, “Kabat numbering” refers to the numbering system set forth by Kabat et al., U.S. Dept, of Health and Human Services, “Sequence of Proteins of Immunological Interest” (1983).
[00213] In addition to table above, the Kabat number system describes the CDR regions as follows: CDR-H1 begins at approximately amino acid 31 (i.e., approximately 9 residues after the first cysteine residue), includes approximately 5-7 amino acids, and ends at the next tryptophan residue. CDR-H2 begins at the fifteenth residue after the end of CDR-H1, includes approximately 16-19 amino acids, and ends at the next arginine or lysine residue. CDR-H3 begins at approximately the thirty third amino acid residue after the end of CDR- H2; includes 3-25 amino acids; and ends at the sequence W-G-X-G, where X is any amino acid. CDR-L1 begins at approximately residue 24 (i.e., following a cysteine residue); includes approximately 10-17 residues; and ends at the next tryptophan residue. CDR-L2 begins at approximately the sixteenth residue after the end of CDR-L1 and includes approximately 7 residues. CDR-L3 begins at approximately the thirty third residue after the end of CDR-L2 (i.e., following a cysteine residue); includes approximately 7-11 residues and ends at the sequence F or W-G-X-G, where X is any amino acid.
[00214] As used herein, the term "epitope" can include any protein determinant that can specifically bind to an immunoglobulin, a scFv, or a T-cell receptor. The variable region allows the antibody to selectively recognize and specifically bind epitopes on antigens. For example, the VL domain and VH domain, or subset of the complementarity determining regions (CDRs), of an antibody combine to form the variable region that defines a three dimensional antigen-binding site. This quaternary antibody structure forms the antigenbinding site present at the end of each arm of the Y. Epitopic determinants can consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. For example, antibodies can be raised against N- terminal or C- terminal peptides of a polypeptide. More specifically, the antigen-binding site is defined by three CDRs on each of the VH and VL chains (i.e. CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2 and CDR-L3). In one embodiment, the antibodies can be directed to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) having Ann UniProt Reference No:
Pl 6410 (CTLA-4_HUMAN) (223 amino acid residues in length), comprising the amino acid sequence of SEQ ID NO: [ ]:
[00215] As used herein, the terms "immunological binding," and "immunological binding properties" can refer to the non-covalent interactions of the type which occur between an immunoglobulin molecule and an antigen for which the immunoglobulin is specific. The strength, or affinity of immunological binding interactions can be expressed in terms of the dissociation constant (Kd) of the interaction, wherein a smaller K represents a greater affinity. Immunological binding properties of selected polypeptides can be quantified using methods well known in the art. One such method entails measuring the rates of antigenbinding site/antigen complex formation and dissociation, wherein those rates depend on the concentrations of the complex partners, the affinity of the interaction, and geometric parameters that equally influence the rate in both directions. Thus, both the "on rate constant" (Kon) and the "off rate constant" (Koff) can be determined by calculation of the concentrations and the actual rates of association and dissociation. (See Nature 361 : 186-87 (1993)). The ratio of Koff /Kon enables the cancellation of all parameters not related to affinity, and is equal to the equilibrium binding constant, KD. (See, generally, Davies et al. (1990) Annual Rev Biochem 59:439-473). An antibody of the invention can specifically bind to a CTLA4 epitope when the equilibrium binding constant (KD) is <1 pM, <10 pM, < 10 nM, < 10 pM, or < 100 pM to about 1 pM, as measured by kinetic assays such as radioligand binding assays or similar assays known to those skilled in the art, such as BIAcore or Octet (BLI). For example, in some embodiments, the KD is between about IE- 12 M and a KD about IE-11 M. In some embodiments, the Kois between about IE- 11 M and a KD about IE- 10 M. In some embodiments, the KD is between about IE- 10 M and a KD about IE-9 M. In some embodiments, the KD is between about IE-9 M and a KD about IE-8 M. In some
embodiments, the KD is between about IE-8 M and a KD about IE-7 M. In some embodiments, the KD is between about IE- 7 M and a KD about IE-6 M. For example, in some embodiments, the Kois about IE-12 M while in other embodiments the Kois about 1E- 11 M. In some embodiments, the KD is about IE- 10 M while in other embodiments the KD is about IE-9 M. In some embodiments, the KD is about IE-8 M while in other embodiments the KD is about IE-7 M. In some embodiments, the KD is about IE-6 M while in other embodiments the KD is about IE- 5 M. In some embodiments, for example, the KD is about 3 E-ll M, while in other embodiments the Kois about 3E-12 M. In some embodiments, the KD is about 6E-11 M. “Specifically binds” or “has specificity to,” can refer to an antibody that binds to an epitope via its antigen-binding domain, and that the binding entails some complementarity between the antigen-binding domain and the epitope. For example, an antibody is said to “specifically bind” to an epitope when it binds to that epitope, via its antigen-binding domain more readily than it would bind to a random, unrelated epitope. [00216] For example, the CTLA4 antibody can be monovalent or bivalent, and can comprise a single or double chain. Functionally, the binding affinity of the CTLA4 antibody is within the range of 1 () M to 10 12 M. For example, the binding affinity of the CTLA4 antibody is from 10 6 M to 10 12 M, from 10 7 M to 10 12 M, from 10 8 M to 10 12 M, from 10 9 M to 10 12 M, from 10 5 M to 10 11 M, from 10 6 M to 10 11 M, from 10 7 M to 10 " M. from 10 8 M to 10 1 1 M. from 10 9 M to 10 1 1 M. from 10 10 M to 10 1 1 M. from IO 5 M to 10 l0M. from 10 6 M to 10 10 M. from 10 7 M to 10 10 M. from 10 8 M to 10 l0M. from 10 9 M to 10 10 M, from 10 5 M to 10 9 M, from 10 6 M to 10 9M, from 10 7 M to 10 9 M, from 10 8 M to 10 9 M, from I0 5 M to 10 8 M, from 10 6 M to 10 8 M, from 10 7 M to 10 8 M, from 10 5 M to 10 7 M, from 10 6 M to 10 7 M, or from 10 5 M to 10 6 M.
[00217] A CTLA-4 protein, or a derivative, fragment, analog, homolog or ortholog thereof, can be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components. A CTLA-4 protein or a derivative, fragment, analog, homolog, or ortholog thereof, coupled to a proteoliposome can be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.
[00218] Those skilled in the art will recognize that it is possible to determine, without undue experimentation, if a human monoclonal antibody has the same specificity as a human monoclonal antibody of the invention by ascertaining whether the former prevents the latter from binding to CTLA-4. For example, if the human monoclonal antibody being tested competes with the human monoclonal antibody of the invention, as shown by a decrease in
binding by the human monoclonal antibody of the invention, then it is likely that the two monoclonal antibodies bind to the same, or to a closely related, epitope.
[00219] Another way to determine whether a human monoclonal antibody has the specificity of a human monoclonal antibody of the invention is to pre-incubate the human monoclonal antibody of the invention with the CTLA-4 protein, with which it is normally reactive, and then add the human monoclonal antibody being tested to determine if the human monoclonal antibody being tested is inhibited in its ability to bind CTLA-4. If the human monoclonal antibody being tested is inhibited then, in all likelihood, it has the same, or functionally equivalent, epitopic specificity as the monoclonal antibody of the invention. Screening of human monoclonal antibodies of the invention can be also carried out by utilizing CTLA-4 and determining whether the test monoclonal antibody is able to neutralize CTLA-4.
[00220] Various procedures known within the art can be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof. (See, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, incorporated herein by reference).
[00221] Antibodies can be purified by well-known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen which is the target of the immunoglobulin sought, or an epitope thereof, can be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia PA, Vol. 14, No. 8 (April 17, 2000), pp. 25-28).
[00222] The term “monoclonal antibody” or “mAb” or “Mab” or “monoclonal antibody composition”, as used herein, can refer to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.
[00223] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent
to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.
[00224] The immunizing agent can include the protein antigen, a fragment thereof or a fusion protein thereof. For example, peripheral blood lymphocytes can be used if cells of human origin are desired, or spleen cells or lymph node cells can be used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (See Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59- 103). Immortalized cell lines can be transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. For example, rat or mouse myeloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.
[00225] Immortalized cell lines that are useful are those that fuse efficiently, support stable high-level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. For example, immortalized cell lines can be murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center (San Diego, California) and the American Type Culture Collection (Manassas, Virginia). Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies. (See Kozbor, J. Immunol, 133:3001 (1984); Brodeur et al, Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63)).
[00226] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. For example, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem, 107:220 (1980). Moreover, in
therapeutic applications of monoclonal antibodies, it is important to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.
[00227] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods. (See Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103). Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.
[00228] The monoclonal antibodies secreted by the subclones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[00229] Monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567 (incorporated herein by reference in its entirety). DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (See U.S. Patent No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
[00230] Fully human antibodies, for example, are antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed "human antibodies" or "fully human antibodies". Human monoclonal antibodies, such as fully human and humanized antibodies, can be prepared by using trioma technique; the human B-cell hybridoma technique (see Kozbor, et al, 1983
Immunol Today 4: 72); and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al, 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies can be utilized and can be produced by using human hybridomas (see Cote, et al, 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R. Liss, Inc., pp. 77-96).
[00231] “Humanized antibodies” can be antibodies from a non-human species (such as mouse), whose amino acid sequences (for example, in the CDR regions) have been modified to increase their similarity to antibody variants produced in humans. Antibodies can be humanized by methods known in the art, such as CDR-grafting. See also, Safdari et al., (2013) Biotechnol Genet Eng Rev., ' 29:175-86. In addition, humanized antibodies can be produced in transgenic plants, as an an inexpensive production alternative to existing mammalian systems. For example, the transgenic plant can be a tobacco plant, i.e., Nicotiania benthamiana, and Nicotiana tabaccum. The antibodies are purified from the plant leaves. Stable transformation of the plants can be achieved through the use of Agrobacterium tumefaciens or particle bombardment. For example, nucleic acid expression vectors containing at least the heavy and light chain sequences are expressed in bacterial cultures, i. e. , A. tumefaciens strain BLA4404, via transformation. Infiltration of the plants can be accomplished via injection. Soluble leaf extracts can be prepared by grinding leaf tissue in a mortar and by centrifugation. Isolation and purification of the antibodies can be readily be performed by many of the methods known to the skilled artisan in the art. Other methods for antibody production in plants are described in, for example, Fischer et al., Vaccine, 2003, 21:820-5; and Ko et al, Current Topics in Microbiology and Immunology, Vol. 332, 2009, pp. 55-78. As such, the invention further provides any cell or plant comprising a vector that encodes the antibody of the invention, or produces the antibody of the invention.
[00232] Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Pat. Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., Proc. Natl. Sci. USA 91:969-973 (1994)), and chain shuffling (U.S. Pat. No. 5,565,332, which is incorporated by reference in its entirety). “Humanization” (also called Reshaping or CDR-grafting) is a well-established technique understood by the skilled artisan for reducing the immunogenicity of monoclonal
antibodies (mAbs) from xenogeneic sources (commonly rodent) and for improving their activation of the human immune system (See, for example, Hou S, Li B, Wang L, Qian W, Zhang D, Hong X, Wang H, Guo Y (July 2008). "Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling". J Biochem. 144 (1): 115-20).
[00233] In addition, antibodies (such as human antibodies) can also be produced using other techniques, including phage display libraries. (See Hoogenboom and Winter, J. Mol. Biol, 227:381 (1991); Marks et al., J. Mol. Biol, 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al., Bio/Technology 10, 779-783 (1992); Lonberg et al., Nature 368 856-859 (1994); Morrison, Nature 368, 812-13 (1994); Fishwild et al, Nature Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology 14, 826 (1996); and Lonberg and Huszar, Intern. Rev. Immunol. 13: 65-93 (1995).
[00234] Human antibodies can additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal's endogenous antibodies in response to challenge by an antigen. (See, PCT publication no. W094/02602 and U.S. Patent No. 6,673,986). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host's genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. A non-limiting example of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publication nos. WO96/33735 and WO96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the
immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv (scFv) molecules.
[00235] Thus, using such a technique, therapeutically useful IgG, IgA, IgM and IgE antibodies can be produced. For an overview of this technology for producing human antibodies, see Lonberg and Huszar Int. Rev. Immunol. 73:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publication nos. WO 98/24893; WO 96/34096; WO 96/33735; U.S. Pat. Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825; 5,661,016; 5,545,806; 5,814,318; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Creative BioLabs (Shirley, NY) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described herein.
[00236] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Patent No. 5,939,598. It can be obtained by a method, which includes deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.
[00237] One method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Patent No. 5,916,771. This method includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.
[00238] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, is disclosed in PCT publication No. WO99/53049.
[00239] The antibody of interest can also be expressed by a vector containing a DNA segment encoding the single chain antibody described herein. Vectors include, but are not
limited to, chemical conjugates such as described in WO 93/64701, which has targeting moiety (e.g. a ligand to a cellular surface receptor), and a nucleic acid binding moiety (e.g. polylysine), viral vectors (e.g. a DNA or RNA viral vector), fusion proteins such as described in PCT/US 95/02140 (WO 95/22618), which is a fusion protein containing a target moiety (e.g. an antibody specific for a target cell) and a nucleic acid binding moiety (e.g. a protamine), plasmids, phage, viral vectors, etc. The vectors can be chromosomal, non- chromosomal or synthetic. Retroviral vectors can also be used, and include moloney murine leukemia viruses. DNA viral vectors can also be used, and include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector (See Geller, A. I. et al, J. Neurochem, 64:487 (1995); Lim, F., et al, in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England) (1995); Geller, A. I. et al, Proc Natl. Acad. Sci.: U.S.A. 90:7603 (1993); Geller, A. I., et al, Proc Natl. Acad. Sci USA 87: 1149 (1990), Adenovirus Vectors (see LeGal LaSalle et al, Science, 259:988 (1993); Davidson, et al, Nat. Genet 3 :219 (1993); Yang, et al, J. Virol. 69:2004 (1995) and Adeno-associated Virus Vectors (see Kaplitt, M. G.. et al, Nat. Genet. 8: 148 (1994).
[00240] Pox viral vectors introduce the gene into the cell’s cytoplasm. Avipox virus vectors result in only a short term expression of the nucleic acid. Adenovirus vectors, adeno- associated virus vectors, and herpes simplex virus (HSV) vectors can be used for introducing the nucleic acid into neural cells. The adenovirus vector results in a shorter term expression (about 2 months) than adeno-associated virus (about 4 months), which in turn is shorter than HSV vectors. The particular vector chosen will depend upon the target cell and the condition being treated. The introduction can be by standard techniques, e.g. infection, transfection, transduction or transformation. Examples of modes of gene transfer include e.g., naked DNA, CaPCh precipitation, DEAE dextran, electroporation, protoplast fusion, lipofection, cell microinjection, and viral vectors.
[00241] The vector can be employed to target essentially any desired target cell. For example, stereotaxic injection can be used to direct the vectors (e.g. adenovirus, HSV) to a desired location. Additionally, the particles can be delivered by intracerebroventricular (icv) infusion using a minipump infusion system, such as a SynchroMed Infusion System. A method based on bulk flow, termed convection, has also proven effective at delivering large molecules to extended areas of the brain and can be useful in delivering the vector to the target cell. (See Bobo et al, Proc. Natl. Acad. Sci. USA 91 :2076-2080 (1994); Morrison et al, Am. J. Physiol. 266:292-305 (1994)). Other methods that can be used include catheters,
intravenous, parenteral, intraperitoneal and subcutaneous injection, and oral or other known routes of administration.
[00242] These vectors can be used to express large quantities of antibodies that can be used in a variety of ways. For example, to detect the presence of CTLA4 in a sample. The antibody can also be used to try to bind to and disrupt a CTLA4 activity.
[00243] In embodiments, the antibodies herein can be delivered to a subject using a genebased approach. For example, the nucleotide sequence of an anti-CTLA4 antibody as described herein can be delivered into a subject using a vector, DNA or RNA. See, for example, Deal, Cailin E., Andrea Carfi, and Obadiah J. Plante. "Advancements in mRNA Encoded Antibodies for Passive Immunotherapy." Vaccines 9.2 (2021): 108. Such methods can allow for the design and generation of more complex antibody molecules with improved and/or added functions.
[00244] Viral vectors such as adenovirus (Ad) and adeno-associated virus (AAV) have been engineered for in vivo mAb expression by replacing part of their genome with nucleic acid sequences encoding the antibody of interest. The term “viral vector” can refer to a nucleic acid vector construct that includes at least one element of viral origin and has the capacity to be packaged into a viral vector particle. The viral vector can contain the nucleic acid encoding an antibody, antigen-binding portion thereof, or CAR as described herein in place of non-essential viral genes. The vector and/or particle may be utilized for the purpose of transferring any nucleic acids into cells either in vitro or in vivo.
[00245] Retroviruses are a common tool for gene delivery. In embodiments, a retrovirus is used to deliver a polynucleotide encoding the antibody to a cell. The term “retrovirus” can refer to an RNA virus that reverse transcribes its genomic RNA into a linear double-stranded DNA copy and subsequently covalently integrates its genomic DNA into a host genome. Once the virus is integrated into the host genome, it is referred to as a “provirus.” The provirus serves as a template for RNA polymerase II and directs the expression of RNA molecules which encode the structural proteins and enzymes needed to produce new viral particles.
[00246] Illustrative retroviruses suitable for use in particular embodiments, include, but are not limited to: Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), Spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma Virus (RSV)) and lentivirus.
[00247] The term “lentivirus” can refer to a group (or genus) of complex retroviruses. Illustrative lentiviruses include, but are not limited to: HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna-maedi virus (VMV) virus; the caprine arthritisencephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV). In one embodiment, HIV based vector backbones (i.e., HIV cis-acting sequence elements) are preferred. In particular embodiments, a lentivirus is used to deliver a polynucleotide comprising a CAR to a cell.
[00248] Gene transfer of the antibody nucleotide sequences themselves, as DNA or RNA, is an alternative option for transient in vivo antibody production. For example, plasmid DNA approaches can utilie an electroporation component to enhance transfection efficiency following IM delivery. Also, mRNA delivery can be used for in vivo expression of antibodies. In embodiments, the mRNA encoding the antibody of interest can be modified, such as optimization of the mRNA codon usage, and lipid nanoparticles can be used for mRNA delivery.
[00249] In an embodiment, the antibodies described herein can be full-length antibodies, containing an Fc region similar to wild-type Fc regions that bind to Fc receptors.
[00250] Techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (See e.g., U.S. Patent No. 4,946,778). In addition, methods can be adapted for the construction of Fab expression libraries (See e.g., Huse, et al, 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen can be produced by techniques known in the art including, but not limited to: (i) an F(ab')2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab')2 fragment; (iii) an Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments. [00251] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies can, for example, target immune system cells to unwanted cells (see U.S. Patent No. 4,676,980), and for treatment of HIV infection (See PCT Publication Nos. W091/00360; WO92/20373). The antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond.
Examples of suitable reagents for this purpose include iminothiolate and methyl-4- mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980. [00252] The antibody of the invention can be modified with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fc region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibodydependent cellular cytotoxicity (ADCC). (See Caron et al, J. Exp Med., 176: 1 191-1 195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992)). Alternatively, an antibody can be engineered that has dual Fc regions and can thereby have enhanced complement lysis and ADCC capabilities. (See Stevenson et al, Anti-Cancer Drug Design, 3 : 219-230 (1989)). In one embodiment, the antibody of the invention has modifications of the Fc region, such that the Fc region does not bind to the Fc receptors. For example, the Fc receptor is Fey receptor. Antibodies with modification of the Fc region such that the Fc region does not bind to Fey, but still binds to neonatal Fc receptor are useful as described herein.
[00253] In certain embodiments, an antibody of the invention can comprise an Fc variant comprising an amino acid substitution which alters the antigen-independent effector functions of the antibody, in particular the circulating half-life of the antibody. Such antibodies exhibit either increased or decreased binding to FcRn when compared to antibodies lacking these substitutions, therefore, have an increased or decreased half-life in serum, respectively. Fc variants with improved affinity for FcRn are anticipated to have longer serum half-lives, and such molecules have useful applications in methods of treating mammals where long half-life of the administered antibody is desired, e.g., to treat a chronic disease or disorder. In contrast, Fc variants with decreased FcRn binding affinity are expected to have shorter haltlives, and such molecules are also useful, for example, for administration to a mammal where a shortened circulation time can be advantageous, e.g., for in vivo diagnostic imaging or in situations where the starting antibody has toxic side effects when present in the circulation for prolonged periods. Fc variants with decreased FcRn binding affinity are also less likely to cross the placenta and, thus, are also useful in the treatment of diseases or disorders in pregnant women. In addition, other applications in which reduced FcRn binding affinity can be desired include those applications in which localization to the brain, kidney, and/or liver is desired. In one embodiment, the Fc variant-containing antibodies can exhibit reduced transport across the epithelium of kidney glomeruli from the vasculature. In another
embodiment, the Fc variant-containing antibodies can exhibit reduced transport across the blood brain barrier (BBB) from the brain, into the vascular space. In one embodiment, an antibody with altered FcRn binding comprises an Fc domain having one or more amino acid substitutions within the "FcRn binding loop" of an Fc domain. The FcRn binding loop is comprised of amino acid residues 280-299 (according to EU numbering). Exemplary amino acid substitutions with altered FcRn binding activity are disclosed in PCT Publication No. WO05/047327 which is incorporated by reference herein. In certain exemplary embodiments, the antibodies, or fragments thereof, of the invention comprise an Fc domain having one or more of the following substitutions: V284E, H285E, N286D, K290E and S304D (EU numbering).
[00254] In some embodiments, mutations are introduced to the constant regions of the mAh such that the antibody dependent cell-mediated cytotoxicity (ADCC) activity of the mAh is altered. For example, the mutation is an LALA mutation in the CH2 domain. In one embodiment, the antibody (e.g., a human mAh, or a bispecific Ab) contains mutations on one scFv unit of the heterodimeric mAh, which reduces the ADCC activity. In another embodiment, the mAh contains mutations on both chains of the heterodimeric mAh, which completely ablates the ADCC activity. For example, the mutations introduced into one or both scFv units of the mAh are LALA mutations in the CH2 domain. These mAbs with variable ADCC activity can be optimized such that the mAbs exhibits maximal selective killing towards cells that express one antigen that is recognized by the mAh, however exhibits minimal killing towards the second antigen that is recognized by the mAh.
[00255] In other embodiments, antibodies of the invention for use in the diagnostic and treatment methods described herein have a constant region, e.g., an IgGi , IgG2, or IgG4 heavy chain constant region, which can be altered to reduce or eliminate glycosylation. For example, an antibody of the invention can also comprise an Fc variant comprising an amino acid substitution which alters the glycosylation of the antibody. For example, the Fc variant can have reduced glycosylation (e.g., N- or O-linked glycosylation). In some embodiments, the Fc variant comprises reduced glycosylation of the N-linked glycan normally found at amino acid position 297 (EU numbering). In another embodiment, the antibody has an amino acid substitution near or within a glycosylation motif, for example, an N-linked glycosylation motif that contains the amino acid sequence NXT or NXS. In a particular embodiment, the antibody comprises an Fc variant with an amino acid substitution at amino acid position 228 or 299 (EU numbering). In more particular embodiments, the antibody comprises an IgGl or IgG4 constant region comprising an S228P and a T299A mutation (EU numbering).
[00256] Exemplary amino acid substitutions which confer reduced or altered glycosylation are described in PCT Publication No, W005/018572, which is incorporated by reference herein in its entirety. In some embodiments, the antibodies of the invention, or fragments thereof, are modified to eliminate glycosylation. Such antibodies, or fragments thereof, can be referred to as "agly" antibodies, or fragments thereof, (e.g. "agly" antibodies). While not wishing to be bound by theory "agly" antibodies, or fragments thereof, can have an improved safety and stability profile in vivo. Exemplary agly antibodies, or fragments thereof, comprise an aglycosylated Fc region of an IgGi antibody which is devoid of Fc-effector function thereby eliminating the potential for Fc mediated toxicity to the normal vital tissues and cells that express CTLA4. In yet other embodiments, antibodies of the invention, or fragments thereof, comprise an altered glycan. For example, the antibody can have a reduced number of fucose residues on an N-glycan at Asn297 of the Fc region, i.e., is afucosylated. In another embodiment, the antibody can have an altered number of sialic acid residues on the N-glycan at Asn297 of the Fc region.
[00257] The invention also is directed to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).
[00258] Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Non-limiting examples include 212Bi, 133I, 131In, 90Y, and 186Re.
[00259] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis- diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro- 2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in
Vitetta et al, Science 238: 1098 (1987). Carbon- 14-labeled l-isothiocyanatobenzyl-3- methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. (See PCT Publication No. WO94/11026, and U.S. Patent No. 5,736,137).
[00260] Those of ordinary skill in the art understand that a large variety of possible moieties can be coupled to the resultant antibodies or to other molecules of the invention. (See, for example, "Conjugate Vaccines", Contributions to Microbiology and Immunology, J. M. Cruse and R. E. Lewis, Jr (eds), Carger Press, New York, (1989), the entire contents of which are incorporated herein by reference).
[00261] Coupling can be accomplished by any chemical reaction that will bind the two molecules so long as the antibody and the other moiety retain their respective activities. This linkage can include many chemical mechanisms, for instance covalent binding, affinity binding, intercalation, coordinate binding, and complexation. In one embodiment, binding is, covalent binding. Covalent binding can be achieved either by direct condensation of existing side chains or by the incorporation of external bridging molecules. Many bivalent or polyvalent linking agents are useful in coupling protein molecules, such as the antibodies of the present invention, to other molecules. For example, representative coupling agents can include organic compounds such as thioesters, carbodiimides, succinimide esters, diisocyanates, glutaraldehyde, diazobenzenes and hexamethylene diamines. This listing is not intended to be exhaustive of the various classes of coupling agents known in the art but, rather, is exemplary of the more common coupling agents. (See Killen and Lindstrom, Jour. Immun. 133 : 1335-2549 (1984); Jansen et al., Immunological Reviews 62: 185-216 (1982); and Vitetta et al, Science 238: 1098 (1987)). Non-limiting examples of linkers are described in the literature. (See, for example, Ramakrishnan, S. et al., Cancer Res. 44:201-208 (1984) describing use of MBS (M-maleimidobenzoyl-N-hydroxysuccinimide ester). See also, U.S. Patent No. 5,030,719, describing use of halogenated acetyl hydrazide derivative coupled to an antibody by way of an oligopeptide linker. Non-limiting examples of useful linkers that can be used with the antibodies of the invention include: (i) EDC (l-ethyl-3- (3 -dimethyl aminopropyl) carbodiimide hydrochloride; (ii) SMPT (4- succinimidyloxycarbonyl-alpha-methyl- alpha-(2-pridyl-dithio)-toluene (Pierce Chem. Co., Cat. (21558G); (iii) SPDP (succinimidyl-6 [3-(2-pyridyldithio) propionamido]hexanoate (Pierce Chem. Co., Cat #21651G); (iv) Sulfo- LC-SPDP (sulfosuccinimidyl 6 [3-(2- pyridyldithio)-propianamide] hexanoate (Pierce Chem. Co. Cat. #2165-G); and (v) sulfo- NHS ( -hydroxysulfo-succinimide: Pierce Chem. Co., Cat. #24510) conjugated to EDC.
[00262] The linkers described herein contain components that have different attributes, thus leading to conjugates with differing physio-chemical properties. For example, sulfo- NHS esters of alkyl carboxylates are more stable than sulfo-NHS esters of aromatic carboxylates. NHS-ester containing linkers are less soluble than sulfo-NHS esters. Further, the linker SMPT contains a sterically hindered disulfide bond, and can form conjugates with increased stability. Disulfide linkages, are in general, less stable than other linkages because the disulfide linkage is cleaved in vitro, resulting in less conjugate available. Sulfo-NHS, in particular, can enhance the stability of carbodimide couplings. Carbodimide couplings (such as EDC) when used in conjunction with sulfo-NHS, forms esters that are more resistant to hydrolysis than the carbodimide coupling reaction alone.
[00263] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al, Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al, Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Patent No. 5,013,556.
[00264] Non-limiting examples of useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab' fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al, J. Biol. Chem, 257: 286-288 (1982) via a disulfide-interchange reaction.
[00265] Multispecific Antibodies (Bispecific and Trispecific)
[00266] Multispecific antibodies are antibodies that can recognize two or more different antigens. For example, a bi-specific antibody (bsAb) is an antibody comprising two variable domains or scFv units such that the resulting antibody recognizes two different antigens. For example, a trispecific antibody (tsAb) is an antibody comprising two variable domains or scFv units such that the resulting antibody recognizes three different antigens. This invention provides for multispecific antibodies, such as bi-specific and trispecific antibodies, that recognize CTLA-4 and a second antigen and/or a third antigen. In one embodiment, multispecific antibodies (e.g., bi-specific antibodies and trispecific antibodies) can comprise CTLA-4 specific fusion proteins encompassing the antibodies described herein. Exemplary second and.or third antigens include tumor associated antigens (e.g., LINGO1), cytokines (e.g., IL-12 (IL-12A (p35 subunit) protein sequence having NCBI Reference No.
NP_000873.2; IL-12B (p40 subunit) protein sequence having NCBI Reference No. NP_002178.2); IL-18 (protein sequence having NCBI Reference no. NP_001553.1); IL-15 (protein sequence having NCBI Reference No. NP_000576.1); IL-7 (protein sequence having NCBI Reference No. NP_000871.1); IL-2 (protein sequence having NCBI Reference No. NP_000577.2); and IL-21 (protein sequence having NCBI Reference No. NP_068575.1)), cytokine cognate receptors (eg., IL-12R), and cell surface receptors. Non-limiting examples of second and/or third antigens include CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX- 40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM (or BTLA), CD47, PDL1, MICA, MICB, and CD73. In one embodiment, the bispecific and trispecific antibodies comprise CTLA-4 fusion proteins. For example, the fusion protein comprises an antibody comprising a variable domain or scFv unit and a ligand or antigen and/or a third ligand or antigen as described herein such that the resulting antibody recognizes an antigen and binds to the ligand-specific receptor. Exemplary antibody compositions (e.g., VH and/or VL sequences or fragments thereof) that are useful for the design of CTLA-4 fusion proteins as described herein include, but are not limited to, anti-CAIX antibodies described in PCT/US2006/046350 and PCT/US2015/067178; anti- CXCR4 antibodies described in PCT/US20006/005691; anti-CCR4 antibodies described in PCT/US2008/088435, PCT/US2013/039744, and PCT/US2015/054202; anti-PD-Ll antibodies described in PCT/US2008/088435 and PCT/US2020/062815; anti-PD-1 antibodies described in PCT/US2020/037791 and PCT/US2020/037781; anti-GITR antibodies described in PCT/US2017/043504; anti-claudin-4 antibodies described in PCT/US2019/022272; and anti-MUCl antibodies described in PCT/US2020/037783 (each of the applications which are incorporated by reference in their entireties). In one embodiment, the fusion protein further comprises a constant region, and/or a linker as described herein. Different formats of multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as a fusion protein comprises an antibody that recognizes CTLA-4 and a ligand) are described herein. Ligands can be tumor associated antigens (e.g., LINGO1, ErbB2 (HER2/neu), carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), MUC1, MSLN, CD 19, CD20, CD30, CD40, CD22, RAGE-1, MN-CA IX, RET1, RET2 (AS), prostate specific antigen (PSA), TAG-72, PAP, p53, Ras, prostein, PSMA, survivin, 9D7, prostate-carcinoma tumor antigen-1 (PCTA-1), GAGE, MAGE, mesothelin, 0-catenin, TGF-0RII, BRCA1/2, SAP-1, HPV-E6, HPV-E7 (see also, PCT/US2015/067225 and PCT/US2019/022272 for additional tumor-associated surface antigens, which are incorporated by reference in their entireties)); cytokines (e.g., IL- 12 (IL-
12A (p35 subunit) protein sequence having NCBI Reference No. NP_000873.2; IL-12B (p40 subunit) protein sequence having NCBI Reference No. NP_002178.2); IL-18 (protein sequence having NCBI Reference no. NP_001553.1); IL-15 (protein sequence having NCBI Reference No. NP_000576.1); IL-7 (protein sequence having NCBI Reference No. NP_000871.1); IL-2 (protein sequence having NCBI Reference No. NP_000577.2); and IL- 21 (protein sequence having NCBI Reference No. NP_068575.1)); CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM (or BTLA), CD47, PDL1, MICA, MICB, and CD73. Different formats of bispecific or trispecific antibodies are also provided herein. In some embodiments, each of the anti-CTLA-4 fragment and the second antigenspecific fragment and/or the third antigen-specific fragment is each independently selected from a Fab fragment, a single-chain variable fragment (scFv), or a single-domain antibody. In some embodiments, the bispecific or trispecific antibody further includes a Fc fragment (e.g., as described in PCT/US2015/021529 and PCT/US2019/023382, each of which are incorporated by reference in their entireties). A bispecific or trispecific antibody of the invention can comprise a heavy chain and a light chain combination or scFv of the CTLA-4 antibodies described herein.
[00267] Multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies) of the invention (for example, an anti-CTLA-4-scFv fusion protein) can be constructed using methods known art. In some embodiments, the bi-specific antibody is a single polypeptide wherein the two scFv fragments are joined by a long linker polypeptide, of sufficient length to allow intramolecular association between the two scFv units to form an antibody. In other embodiments, the bi-specific antibody is more than one polypeptide linked by covalent or non-covalent bonds. In some embodiments, the amino acid linker depicted herein (GGGGSGGGGS; “(G4S)2” (SEQ ID NO: [ ])) can be generated with a longer G4S linker to improve flexibility. For example, the linker can also be “(G4S)3” (e.g., GGGGSGGGGSGGGGS (SEQ ID NO: [ ])); “(G4S)4” (e.g., GGGGSGGGGSGGGGSGGGGS) (SEQ ID NO: [ ]); “(G4S)5” (e.g., GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: [ ])); “(G4S)6” (e.g., GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: [ ])); “(G4S)7” (e g., GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO: [ ])); and the like. For example, use of the (G4S)5 linker can provide more flexibility to a ligand described herein and can improve expression. In some embodiments, the linker can also be (GS)n, (GGS)n, (GGGS)n, (GGSG)n, (GGSGG)n, or (GGGGS)n, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9,
or 10. Non-limiting examples of linkers known to those skilled in the art that can be used to construct the fusions described herein can be found in U.S. Patent No. 9,708,412; U.S. Patent Application Publication Nos. US 20180134789 and US 20200148771; and PCT Publication No. WO2019051122 (each of which are incorporated by reference in their entireties).
[00268] In another embodiment, the multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) can be constructed using the "knob into hole" method (Ridgway et al, Protein Eng 7:617-621 (1996)). In this method, the Ig heavy chains of the two different variable domains are reduced to selectively break the heavy chain pairing while retaining the heavy-light chain pairing. The two heavy -light chain heterodimers that recognize two different antigens/ligands or three different antigens/ligands are mixed to promote heteroligation pairing, which is mediated through the engineered "knob into holes" of the CH3 domains.
[00269] In another embodiment the multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) can be constructed through exchange of heavy-light chain dimers from two or more different antibodies to generate a hybrid antibody where the first heavy -light chain dimer recognizes CTLA-4 and the second heavy -light chain dimer recognizes a second antigen and/or third antigen. The mechanism for heavy -light chain dimer is similar to the formation of human IgG4, which also functions as a bispecific molecule. Dimerization of IgG heavy chains is driven by intramolecular force, such as the pairing the CH3 domain of each heavy chain and disulfide bridges. Presence of a specific amino acid in the CH3 domain (R409) has been shown to promote dimer exchange and construction of the IgG4 molecules. Heavy chain pairing is also stabilized further by interheavy chain disulfide bridges in the hinge region of the antibody. Specifically, in IgG4, the hinge region contains the amino acid sequence Cys-Pro-Ser-Cys (in comparison to the stable IgGl hinge region which contains the sequence Cys-Pro-Pro-Cys) at amino acids 226- 230. This sequence difference of Serine at position 229 has been linked to the tendency of IgG4 to form intrachain disulfides in the hinge region (Van der Neut Kolfschoten, M. et al, 2007, Science 317: 1554-1557 and Labrijn, A.F. et al, 2011, Journal of Immunol 187:3238- 3246).
[00270] The multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) of the invention can be created through introduction of the R409 residue in the CH3 domain and the Cys-Pro-Ser-Cys sequence in the hinge region of antibodies that recognize CTLA-4 or a second and/or third antigen, so that the heavy-light chain dimers exchange to produce an antibody molecule with one heavy-light chain dimer
recognizing CTLA-4 and the second heavy-light chain dimer recognizing a second and/or third antigen, wherein the second and/or third antigen (or ligand) is any antigen (or ligand) disclosed herein. Known IgG4 molecules can also be altered such that the heavy and light chains recognize CTLA-4 or a second and/or third antigen, as disclosed herein. Use of this method for constructing the multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) of the invention can be beneficial due to the intrinsic characteristic of IgG4 molecules wherein the Fc region differs from other IgG subtypes in that it interacts poorly with effector systems of the immune response, such as complement and Fc receptors expressed by certain white blood cells. This specific property makes these IgG4-based multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) attractive for therapeutic applications, in which the antibody is required to bind the target(s) and functionally alter the signaling pathways associated with the target(s), however not trigger effector activities.
[00271] The multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) described herein can be engineered with a non-depleting heavy chain isotype, such as IgGl-LALA or stabilized IgG4 or one of the other non-depleting variants. In some embodiments, mutations are introduced to the constant regions of the bsAb such that the antibody dependent cell-mediated cytotoxicity (ADCC) activity of the bsAb is altered. For example, the mutation is a LALA mutation in the CH2 domain. In one aspect, the multispecific antibody (e.g., bispecific antibodies and trispecific antibodies such as anti- CTLA-4-scFv fusions) contains mutations on one scFv unit of the heterodimeric multispecific antibody, which reduces the ADCC activity. In another aspect, the multispecific antibody (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) contains mutations on both chains of the heterodimeric multispecific antibody, which completely ablates the ADCC activity. For example, the mutations introduced in one or both scFv units of the multispecific antibody (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) are LALA mutations in the CH2 domain. These multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti- CTLA-4-scFv fusions) with variable ADCC activity can be optimized such that the multispecific antibodies exhibit maximal selective killing towards cells that express one antigen that is recognized by the multispecific antibody, however, exhibits minimal killing towards the second antigen that is recognized by the multispecific antibody.
[00272] The multispecific antibodies (e.g., bispecific antibodies) described herein can be engineered as modular tetrameric bispecific antibodies (tBsAb). See, for example, WO
2018/071913, which is incorporated by reference herein in its entirety. For example, the tetravalent antibody can be a dimer of a bispecific scFv fragment including a first binding site for a first antigen, and a second binding site for a second antigen. In embodiments, the anti- CTLA-4 antibody can be the first binding site for a first antigen. In embodiments, the anti- CTLA-4 antibody can be the second binding site for a second antigen. The two binding sites can be joined together via a linker domain. In embodiments, the scFv fragment is a tandem scFv, the linker domain includes an immunoglobulin hinge region (e.g., an IgGl, an IgG2, an IgG3, or an IgG4 hinge region) amino acid sequence. In embodiments, the immunoglobulin hinge region amino acid sequence can be flanked by a flexible linker amino acid sequence, e.g., having the linker amino acid sequence (GGGS)xi-e, (GGGGS)xi-e, or GSAGSAAGSGEF. In embodiments, the linker domain includes at least a portion of an immunoglobulin Fc domain, e.g., an IgGl, an IgG2, an IgG3, or an IgG4 Fc domain. In embodiments, the at least a portion of the immunoglobulin Fc domain does not include a CH2 domain. In embodiments, the at least a portion of the immunoglobulin Fc domain can be a CH2 domain. An exemplary CH2 domain amino acid sequence includes APELLGGPDVFLF (SEQ ID NO: [ ]). The Fc domain can be linked to the C-terminus of an immunoglobulin hinge region (e.g., an IgGl, an IgG2, an IgG3, or an IgG4 hinge region) amino acid sequence. The linker domain can include a flexible linker amino acid sequence (e.g., (GGGS)xi-e, (GGGGS)xi-e, or GSAGSAAGSGEF (SEQ ID NO: [ ])) at one terminus or at both termini. [00273] In embodiments, the multispecific antibodies (e.g., bispecific antibodies) described herein can be engineered with a wild type Fc region, or a modified Fc region. For example, embodiments can comprise an IgGs CH2 domain. In other embodiments, the multispecific antibodies (e.g., bispecific antibodies) are engineered without an Fc domain and/or Fc fragment.
[00274] In embodiments, the tBsAb can be specific for CTLA-4, and also a target selected from the group consisting of B7H3, B7H4, CD27, CD28, CD40, CD40L, CD47, CD122, CCR4, CTLA-4, GITR, GITRL, ICOS, ICOSL, LAG-3, LIGHT, OX-40, OX40L, PD-L1, PD-1, TIM3, 4-1BB, TIGIT, VISTA, HEVM, BTLA, MICA, MICB, and KIR.
[00275] The multispecific antibodies (e.g., bispecific antibodies and trispecific antibodies such as anti-CTLA-4-scFv fusions) disclosed herein can be useful in treatment of chronic infections, diseases, or medical conditions, for example, cancer.
[00276] Use of Antibodies Against CTLA-4
[00277] Antibodies of the invention specifically binding a CTLA-4 protein, or a fragment thereof, can be administered for the treatment of a CTLA-4 associated disease or disorder. A "CTLA-4-associated disease or disorder" includes disease states and/or symptoms associated with a disease state, where increased levels of CTLA-4 and/or activation of cellular signaling pathways involving CTLA-4 are found. In some embodiments, the cancer can be lung cancer, kidney cancer, ovarian cancer, prostate cancer, colon cancer, breast cancer, cervical cancer, uterine cancer, brain cancer, skin cancer, liver cancer, pancreatic cancer, glioblastoma multiforme, cutaneous squamous cell carcinoma, melanoma, renal cancer, such as clear cell renal cell carcinoma, or stomach cancer.
[00278] Antibodies of the invention, including bi-specific, polyclonal, monoclonal, humanized and fully human antibodies, can be used as therapeutic agents. Such agents will generally be employed to treat cancer in a subject, increase vaccine efficiency or augment a natural immune response. An antibody preparation, for example, one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Administration of the antibody can abrogate or inhibit or interfere with an activity of the CTLA-4 protein.
[00279] Pharmaceutical Compositions
[00280] Antibodies of the invention specifically binding a CTLA-4 protein or fragment thereof can be administered for the treatment of a cancer in the form of pharmaceutical compositions. Principles and considerations involved in preparing therapeutic pharmaceutical compositions comprising the antibody, as well as guidance in the choice of components are provided, for example, in: Remington: The Science And Practice Of Pharmacy 20th ed. (Alfonso R._Gennaro, et al, editors) Mack Pub. Co., Easton, Pa., 2000; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.
[00281] A specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the particular antibodies, variant or derivative thereof used, the patient's age, body weight, general health, sex, and diet, and the time of administration, rate of excretion, drug combination, and the severity of the particular disease being treated. Judgment of such factors by medical caregivers is within the ordinary skill in the art. The amount will also depend on the individual patient to be treated, the route of administration, the type of formulation, the characteristics of the compound used, the severity
of the disease, and the desired effect. The amount used can be determined by pharmacological and pharmacokinetic principles well known in the art.
[00282] A therapeutically effective amount of an antibody of the invention can be the amount needed to achieve a therapeutic objective. As noted herein, this can be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. The dosage administered to a subject (e.g., a patient) of the antigen-binding polypeptides described herein is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight, between 0.1 mg/kg and 20 mg/kg of the patient's body weight, or 1 mg/kg to 10 mg/kg of the patient's body weight. Human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the disclosure may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention can be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies can range, for example, from twice daily to once a week.
[00283] Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. (See, e.g., Marasco et al, Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993)). The formulation can also contain more than one active compound as necessary for the particular indication being treated, for example, those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine (e.g. IL-15), chemotherapeutic agent, or growth- inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
[00284] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.
[00285] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
[00286] Sustained-release preparations can be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. , films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers ofL-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While polymers such as ethylenevinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
[00287] The antibodies or agents of the invention (also referred to herein as "active compounds"), and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such pharmaceutical compositions can comprise the antibody or agent and a pharmaceutically acceptable carrier. As used herein, the term "pharmaceutically acceptable carrier" can include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Non-limiting examples of such carriers or diluents include water, saline, ringer's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils can also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
[00288] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
[00289] Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™(BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In embodiments, the composition is sterile and is fluid to the extent that easy syringeability exists. It can be stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, isotonic agents can be included, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
[00290] Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients
enumerated above, as required, followed by filtered sterilization. For example, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. [00291] Oral compositions can include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or com starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
[00292] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
[00293] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.
[00294] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
[00295] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release
formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polygly colic acid, collagen, poly orthoesters, and polylactic acid. Methods for preparation of such formulations are apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[00296] Oral or parenteral compositions can be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
[00297] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.
[00298] Diagnostics
[00299] An antibody according to the invention can be used as an agent for detecting the presence of CTLA-4 (or a protein fragment thereof) in a sample. For example, the antibody can contain a detectable label. Antibodies can be polyclonal or monoclonal. An intact antibody, or a fragment thereof (e.g., Fab, scFv, or F(ab)2) can be used. The term "labeled", with regard to the probe or antibody, can encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" can include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term "biological
sample", therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA includes Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations.
[00300] Procedures for conducting immunoassays are described, for example in "ELISA: Theory and Practice: Methods in Molecular Biology", Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; "Immunoassay", E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, CA, 1996; and "Practice and Theory of Enzyme Immunoassays", P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
[00301] Antibodies directed against a CTLA-4 protein (or a fragment thereof) can be used in methods known within the art relating to the localization and/or quantitation of a CTLA-4 protein (e.g., for use in measuring levels of the CTLA-4 protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a CTLA-4 protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to herein as "therapeutics").
[00302] An antibody of the invention specific for a CTLA-4 protein can be used to isolate a CTLA-4 polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. Antibodies directed against a CTLA-4 protein (or a fragment thereol) can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen.
[00303] Detection can be facilitated by coupling (i.e., physically linking) the antibody to a detectable substance. Examples of detectable substances include, but are not limited to, various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Non-limiting examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, [3-galactosidase, or
acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include 125I, 131I, 35S, 32P or 3H.
[00304] Cellular therapies
[00305] Cellular therapies are also provided here. For example, cellular therapies can include cells, such as T cells NK cells, or B cells, genetically engineered to express an anti- CTLA4 antibody as described herein. A “genetically engineered cell” can refer to any cell of any organism that is modified, transformed, or manipulated by addition or modification of a gene, a DNA or RNA sequence, or protein or polypeptide. Isolated cells, host cells, and genetically engineered cells can include isolated immune cells, such as NK cells, T cells, and B cells, that contain the DNA or RNA sequences encoding an antibody as described herein, and/or a chimeric receptor or chimeric receptor complex that is expressed on the cell surface. [00306] A “T cell" is a cell of the immune system that matures in the thymus and produces T cell receptors (TCR). T cells can be naive cells (not in contact with the antigen; increased expression of CD62L, CCR7, CD28, CD3, CD127 and CD45RA and reduced expression of CD45RO compared to T CM ), memory T cells (T M ) (contacted with antigen and long-living) and effector cells (in contact with the antigen, cytotoxic). T M can be further subdivided into subpopulations of central memory T cells (T CM , increased expression of CD62L, CCR7, CD28, CD127, CD45RO and CD95 and decreased expression of CD54RA compared to naive T cells) and effector memory T cells (T EM , reduced expression of CD62L, CCR7, CD28, CD45RA and increased expression of CD 127 compared to naive T cells or T CM ). Effector T cells (T E ) can refer to CD8 + antigen-contacted cytotoxic T lymphocytes that have reduced expression of CD62L, CCR7, CD28 and are positive for granzyme and perforin compared to T CM .
[00307] T-cells can be obtained from a number of sources, including peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue and tumours. In certain embodiments, T-cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled person, such as FICOLL™ separation. In one embodiment, cells from the circulating blood of a subject are obtained by apheresis. The
apheresis product typically contains lymphocytes, including T-cells, monocytes, granulocytes, B-cells, other nucleated white blood cells, red blood cells and platelets. In one embodiment, the cells collected by apheresis can be washed to remove the plasma fraction and placed in an appropriate buffer or media for subsequent processing. In one embodiment of the invention, the cells are washed with PBS. In an alternative embodiment, the washed solution lacks calcium and/or magnesium or can lack many if not all divalent cations. As would be appreciated by those of ordinary skill in the art, a washing step can be accomplished by methods known to those in the art, such as by using a semi-automated flow- through centrifuge, for example, the Cobe 2991 cell processor, the Baxter CytoMate, or the like. After washing, the cells can be resuspended in a variety of biocompatible buffers or other saline solution with or without buffer. In certain embodiments, the undesirable components of the apheresis sample can be removed and the cell directly resuspended in culture media.
[00308] In embodiments, T-cells are isolated from PBMCs. PBMCs may be isolated from buffy coats obtained by density gradient centrifugation of whole blood, for instance centrifugation through a LYMPHOPREP™ gradient, a PERCOLL™ gradient or a FICOLL™ gradient. T-cells may be isolated from PBMCs by depletion of the monocytes, for instance by using CD14 DYNABEADS®. In some embodiments, red blood cells may be lysed prior to the density gradient centrifugation.
[00309] An "NK cell" is a large granular lymphocyte, being a cytotoxic lymphocyte derived from the common lymphoid progenitor which does not naturally comprise an antigen-specific receptor (e.g. a T-cell receptor or a B-cell receptor). NK cells can be characterised by their CD3-, CD56+ phenotype. In embodiments, NK cell can refer to any known NK cell or any NK-like cell or any cell having the characteristics of an NK cell. Thus primary NK cells can be used or, in another embodiment, a NK cell known in the art that has previously been isolated and cultured can be used. Thus an NK cell-line can be used. A number of different NK cells are known and reported in the literature and any of these could be used, or a cellline may be prepared from a primary NK cell, for example by viral transformation (Vogel et al. 2014, Leukemia 28:192-195). Suitable NK cells include (but are by no means limited to), in addition to NK-92, the NK-YS, NK-YT, MOTN-1 , NKL, KHYG-1 , HANK-1 , or NKG cell lines. Variants of other cell lines may also be used.
[00310] A “B-cell” is a B lymphocyte that, subsequent to activation, can produce antibody molecules. Activation of a B cell can be, without limitation, by recognition of an antigen by an antigen specific immunoglobulin receptor on the B cell surface or by a non-specific
stimulus, e.g., a B cell mitogen such as lipopolysaccharide or pokeweed mitogen. Thus, a B cell can be a “virgin” B lymphocyte that has never previously been activated or a “memory” B lymphocyte that has previously been activated or the progeny of such a B lymphocyte. [00311] Cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies or chimeric antigen receptor (CAR) NK-cell therapies, are also provided herein. CAR T-cell therapies redirect a patient’s T-cells and NK cells to kill tumor cells by the exogenous expression of a CAR on a T-cell or NK cell, for example. For example, when expressed in a T or NK cell, CARs have the ability to redirect T or NK cell specificity and reactivity toward a selected target in a non-MHC-restricted manner, exploiting the antigen-binding properties of monoclonal antibodies. The non-MHC-restricted antigen recognition gives T or NK cells expressing CARs the ability to recognize an antigen independent of antigen processing, thus bypassing a major mechanism of tumor escape.
[00312] A CAR can be a membrane spanning fusion protein that links the antigen recognition domain of an antibody to the intracellular signaling domains of the T-cell receptor and co-receptor. A suitable cell can be used, for example, that can secrete an anti- CTLA-4 antibody of the invention (or alternatively engineered to express an anti-CTLA-4 antibody as described herein to be secreted). The anti- CTLA-4 “payloads” to be secreted, can be, for example, minibodies, scFvs, IgG molecules, bispecific fusion molecules, and other antibody fragments as described herein. Upon contact or engineering, the cell described herein can then be introduced to a patient in need of a treatment by infusion therapies known to one of skill in the art. The patient can have a CTLA-4-associated disease or disorder as described herein, such as chronic infections or cancer. The cell (e.g., a T cell or NK cell) can be, for instance, T lymphocyte, a CD4+ T cell, a CD8+ T cell, or the combination thereof, without limitation. Exemplary CARs and CAR factories useful in aspects of the invention include those disclosed in, for example, PCT/US2015/067225 and PCT/US2019/022272, each of which are hereby incorporated by reference in their entireties. In one embodiment, the CTLA-4 antibodies discussed herein can be used in the construction of multi-specific antibodies or as the payload for a genetically engineered cell, such as a CAR-T cell, a CARNK cell, or a genetically engineered B cell. For example, in one embodiment, the anti-CTLA-4 antibodies discussed herein can be used for the targeting of the CARS (i.e., as the targeting moiety). In another embodiment, the anti- CTLA-4 antibodies discussed herein can be used as the targeting moiety, and a different CTLA-4 antibody that targets a different epitope can be used as the payload. In another embodiment, the payload can be an immunomodulatory antibody payload.
[00313] Methods of Treatment
[00314] As used herein, the terms “treat” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of cancer. Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e. , not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. “Treatment” can refer to prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
[00315] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a cancer (for example, if an early detection cancer biomarker is identified in such a subject), or other cell proliferation-related diseases or disorders. Such diseases or disorders include but are not limited to, e.g., those diseases or disorders associated with aberrant expression of CTLA-4. For example, the methods are used to treat, prevent or alleviate a symptom of cancer. In an embodiment, the methods are used to treat, prevent or alleviate a symptom of a solid tumor. Non-limiting examples of other tumors that can be treated by compositions described herein comprise lung cancer (e.g., nonsmall cell lung cancer or lung adenocarcinoma), gastric cancer, colorectal cancer, bladder cancer, breast cancer, ovarian cancer, prostate cancer, colon cancer, cervical cancer, brain cancer, skin cancer, liver cancer, pancreatic cancer, esophageal squamous cell carcinoma, nasopharyngeal carcinoma, glioblastoma multiforme, squamous cell carcinoma, melanoma, renal cell carcinoma, urothelial carcinoma, hepatocellular carcinoma, malignant pleural mesothelioma, and liquid tumors or stomach cancer. Additionally, the methods of the invention can be used to treat hematologic cancers such as leukemia and lymphoma. Alternatively, the methods can be used to treat, prevent or alleviate a symptom of a cancer that has metastasized. For example, cancers that can be treated or prevented or for which symptons can be alleviated include B-cell chronic lymphocytic leukemia (CLL), non-smallcell lung cancer, melanoma, ovarian cancer, lymphoma, or renal-cell cancer. Cancers that can also be treated or prevented or for which symptons can be alleviated include those solid tumors with a high mutation burden and WBC in filtrate.
[00316] Accordingly, in one aspect, the invention provides methods for preventing, treating or alleviating a symptom cancer or a cell proliferative disease or disorder in a subject by administering to the subject a monoclonal antibody, scFv antibody or bi- specific antibody of the invention. For example, an anti- CTLA-4 antibody can be administered in therapeutically effective amounts.
[00317] Subjects at risk for cancer or cell proliferation-related diseases or disorders can include patients who have a family history of cancer or a subject exposed to a known or suspected cancer-causing agent. Administration of a prophylactic agent can occur prior to the manifestation of cancer such that the disease is prevented or, alternatively, delayed in its progression.
[00318] In another aspect, tumor cell growth is inhibited by contacting a cell with an anti- CTLA4 antibody of the invention. The cell can be any cell that expresses CTLA-4.
[00319] Also included in the invention are methods of increasing or enhancing an immune response to an antigen. An immune response is increased or enhanced by administering to the subject a monoclonal antibody, scFv antibody, or bi-specific antibody of the invention. The immune response is augmented for example by augmenting antigen specific T effector function. The antigen is a viral (e.g. HIV), bacterial, parasitic or tumor antigen. The immune response is a natural immune response. By natural immune response is meant an immune response that is a result of an infection. The infection is a chronic infection. Increasing or enhancing an immune response to an antigen can be measured by a number of methods known in the art. For example, an immune response can be measured by measuring any one of the following: T cell activity, T cell proliferation, T cell activation, production of effector cytokines, and T cell transcriptional profile. Alternatively, the immune response is a response induced due to a vaccination.
[00320] Accordingly, in another aspect the invention provides a method of increasing vaccine efficiency by administering to the subject a monoclonal antibody or scFv antibody of the invention and a vaccine. The antibody and the vaccine are administered sequentially or concurrently. The vaccine is a tumor vaccine a bacterial vaccine or a viral vaccine.
[00321] Combinatory Methods
[00322] Compositions of the invention as described herein can be administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the compositions of the disclosure include, but are not limited to, antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens
(e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate); hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g., dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).
[00323] In additional embodiments, the compositions of the invention as described herein can be administered in combination with cytokines. Cytokines that may be administered with the compositions include, but are not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL- 10, IL- 12, IL-13, IL-15, anti-CD40, CD40L, and TNF-a.
[00324] In additional embodiments, the compositions described herein can be administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.
[00325] In some embodiments, the compositions described herein can be administered in combination with other immunotherapeutic agents. Non-limiting examples of immunotherapeutic agents include simtuzumab, abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, namatumab, naptumomab, necitumumab, nimotuzumab, nofetumomab, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, solitomab, tacatuzumab,
taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, CC49, and 3F8.
[00326] The invention provides for methods of treating cancer in a patient by administering two antibodies that bind to the same epitope of the CTLA-4 protein or, alternatively, two different epitopes of the CTLA-4 protein. Alternatively, the cancer can be treated by administering a first antibody that binds to CTLA-4 and a second antibody that binds to a protein other than CTLA-4. In other embodiments, the cancer can be treated by administering a bispecific antibody that binds to CTLA-4 and that binds to a protein other than CTLA-4. For example, the other protein other than CTLA-4 can include, but is not limited to, IL-12, IL-12R, IL-2, IL-2R, IL-15, IL-15R, IL-7, IL-7R, IL-21, or IL-21R. For example, the other protein other than CTLA-4 is a tumor- associated antigen; the other protein other than CTLA-4 can also be a cytokine.
[00327] In some embodiments, the invention provides for the administration of an anti-PD- 1 antibody alone or in combination with an additional antibody that recognizes another protein other than CTLA-4, with cells that are capable of effecting or augmenting an immune response. For example, these cells can be peripheral blood mononuclear cells (PBMC), or any cell type that is found in PBMC, e.g., cytotoxic T cells, macrophages, and natural killer (NK) cells.
[00328] Additionally, the invention provides administration of an antibody that binds to the CTLA4 protein and an anti-neoplastic agent, such as a small molecule, a growth factor, a cytokine or other therapeutics including biomolecules such as peptides, peptidomimetics, peptoids, polynucleotides, lipid-derived mediators, small biogenic amines, hormones, neuropeptides, and proteases. Small molecules include, but are not limited to, inorganic molecules and small organic molecules. Suitable growth factors or cytokines include an IL-2, GM-CSF, IL-12, and TNF-alpha. Small molecule libraries are known in the art. (See, Lam, Anticancer Drug Des., 12: 145, 1997.)
[00329] Chimeric antisen receptor (CAR) T-cell therapies
[00330] Cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, are also provided herein. CAR T-cell therapies redirect a patient’s T-cells to kill tumor cells by the exogenous expression of a CAR on a T-cell, for example. A CAR can be a membrane spanning fusion protein that links the antigen recognition domain of an antibody to the intracellular signaling domains of the T-cell receptor and co-receptor. A suitable cell can be
used, for example, that can secrete an anti-CTLA-4 antibody of the present invention (or alternatively engineered to express an anti-CTLA-4 antibody as described herein to be secreted). The anti-CTLA-4 “payloads” to be secreted, can be, for example, minibodies, ScFvs, IgG molecules, bispecific fusion molecules, and other antibody fragments as described herein.
[00331] Solid tumors offer unique challenges for CAR-T therapies. Some barriers to CAR- T effectiveness in solid tumors include heterogeneous antigen expression, insufficient tissue homing, activation, persistence, and the immunosuppressive tumor microenvironment. Unlike blood cancers, tumor-associated target proteins are overexpressed between the tumor and healthy tissue resulting in on-target/off-tumor T-cell killing of healthy tissues. Furthermore, immune repression in the tumor microenvironment (TME) limits the activation of CAR-T cells towards killing the tumor. Upon such contact or engineering, the cell can then be introduced to a cancer patient in need of a treatment by infusion therapies known to one of skill in the art. The cancer patient may have a cancer of any of the types as disclosed herein. The cell (e.g., a T cell) can be, for instance, a tumor-infiltrating T lymphocyte, a CD4+ T cell, a CD8+ T cell, or the combination thereof, without limitation.
[00332] Exemplary CARs and CAR factories useful in aspects of the invention include those disclosed in, for example, PCT/US2015/067225 and PCT/US2019/022272, each of which are hereby incorporated by reference in their entireties. For example, CAR-T cells can be generated according to methods known in the art using lentivirus systems (via transduction), retrovirus systems (via transfection (electroporation)), and transposon systems (via PiggyBac). Useful for promoters for payloads that can be used in the generating of CAR-Ts or CAR NKs include, for example, constitutive promoters (where the promoter is the same as for CAR-T or CAR NK, such as EFla then IRES or 2A); inducible promoters (where the promoter is different from the promoter for CAR-T, such as NF AT, IL-2 prom); and genetically engineered promoters (such as a CTLA-4 locus “knock in” of cytokine and/or a promoter that is under the control of an endogenous promoter). In one embodiment, the CTLA-4 antibodies or the CTLA-4 fusion proteins discussed herein can be used in the construction of multi-specific antibodies or as the payload for a genetically engineered cell, such as a CAR-T cell, CAR NK cell, or genetically engineered B cell. For example, in one embodiment, the anti-CTLA-4 antibodies or the CTLA-4 fusion proteins discussed herein can be used for the targeting of the CARS (i.e., as the targeting moiety). In one embodiment, the anti-CTLA-4 antibodies or the CTLA-4 fusion proteins discussed herein can be used as a payload to be secreted by a genetically engineered cell, such as a CAR-T cell, a CAR NK
cell, or a genetically engineered B cell. In another embodiment, the anti-CTLA-4 antibodies or the CTLA-4 fusion proteins discussed herein can be used as the targeting moiety, and a different CTLA-4 antibody that targets a different epitope can be used as the payload. In another embodiment, the payload can be an immunomodulatory antibody payload. In some embodiments, the CTLA-4 antibodies or the CTLA-4 fusion proteins as described herein for use in CAR-T compositions are not high-affinity CTLA-4 antibodies (for example, so that the antibody does not bind strongly to its CTLA-4 target). For example, the CTLA-4 antibodies or the CTLA-4 fusion proteins described herein can be used as a payload secreted by the genetically engineered cell, such as a CAR-T cell, a CAR-NK cell, or a genetically engineered B cell, with the two targeting moieties (for example, tumor-associated surface antigens) selected for a specific cancer (i.e. MSLN and MUC1 for ovarian cancer). Nonlimiting examples of a tumor-associated surface antigen include ErbB2 (HER2/neu), carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), epidermal growth factor receptor (EGFR), MUC1, MSLN, CD 19, CD20, CD30, CD40, CD22, RAGE-1, MN-CA IX, RET1, RET2 (AS), prostate specific antigen (PSA), TAG-72, PAP, p53, Ras, prostein, PSMA, survivin, 9D7, prostate-carcinoma tumor antigen-1 (PCTA-1), GAGE, MAGE, mesothelin, 0-catenin, TGF-0RII, BRCA1/2, SAP-1, HPV-E6, HPV-E7 (see also, PCT/US2015/067225 and PCT/US2019/022272 for additional tumor-associated surface antigens, which are incorporated by reference in their entireties). Exemplary armored CAR-T cells are listed in the table below.
CART Payload Format Promoter Publication
PSMA DN-TGFb Molecular Therapy 26: 1855 (2018)
CD19 PD-1 nature biotechnology 36:847 (2018)
Mucl6
CD19 IL-18 Cell Reports 23:2130 (2018)
Mucl6
CD19 IL-12 fusion IRES Scientific REPOrTS 7: 10541 (2017)
[00333] In one embodiment, bispecific (or dual -targeted) CAR-Ts are provided. In another embodiment, the CAR-T is an engineered cell comprising a chimeric antigen receptor, wherein the chimeric antigen receptor comprises an extracellular ligand binding domain that is specific for a first antigen and a second antigen on the surface of a cancer cell, wherein the first antigen comprises CXCR4 and the second antigen comprises CLDN4, or the first antigen comprises CAIX and the second antigen comprises CD70, or the first antigen comprises MUC1 and the second antigen comprises Msln. For example, the anti-CTLA-4 antibodies or the CTLA-4 fusion proteins described herein can be used as a payload for a genetically engineered cell, such as a CAR-T, CAR-NK cell or genetically engineered B cell as described herein. In one embodiment, a CXCR4/CLDN4 dual targeting CAR-T with an anti-CTLA-4 fusion payload can be used for breast cancer. In one embodiment, a CAIX/CD70 dual targeting CAR-T with an anti-CTLA-4 fusion payload can be used for clear cell renal cell carcinoma (ccRCC). In one embodiment, a MUCl/Msln dual targeting CAR-T with an anti-CTLA-4 fusion payload can be used for ovarian cancer.
[00334] Diagnostic Assays
[00335] The anti-CTLA-4 antibodies can be used diagnostically to, for example, monitor the development or progression of cancer as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment and/or prevention regimen.
[00336] In some embodiments, for diagnostic purposes, the anti-CTLA-4 antibody of the invention is linked to a detectable moiety, for example, so as to provide a method for detecting a cancer cell in a subject at risk of or suffering from a cancer.
[00337] The detectable moieties can be conjugated directly to the antibodies or fragments, or indirectly by using, for example, a fluorescent secondary antibody. Direct conjugation can be accomplished by standard chemical coupling of, for example, a fluorophore to the antibody or antibody fragment, or through genetic engineering. Chimeras, or fusion proteins can be constructed which contain an antibody or antibody fragment coupled to a fluorescent
or bioluminescent protein. For example, Casadei, et al, (Proc Natl Acad Sci U S A. 1990 Mar; 87(6): 2047 -51) describe a method of making a vector construct capable of expressing a fusion protein of aequorin and an antibody gene in mammalian cells.
[00338] As used herein, the term "labeled", with regard to the probe or antibody, can encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently -labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term "biological sample" is intended to include tissues, cells and biological fluids isolated from a subject (such as a biopsy), as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect cells that express CTLA-4 in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of CTLA-4 include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. Furthermore, in vivo techniques for detection of CTLA-4 include introducing into a subject a labeled anti-CTLA-4 antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.
[00339] In the case of "targeted" conjugates, that is, conjugates which contain a targeting moiety — a molecule or feature designed to localize the conjugate within a subject or animal at a particular site or sites, localization can refer to a state when an equilibrium between bound, "localized", and unbound, "free" entities within a subject has been essentially achieved. The rate at which such equilibrium is achieved depends upon the route of administration. For example, a conjugate administered by intravenous injection can achieve localization within minutes of injection. On the other hand, a conjugate administered orally can take hours to achieve localization. Alternatively, localization can simply refer to the location of the entity within the subject or animal at selected time periods after the entity is administered. By way of another example, localization is achieved when an moiety becomes distributed following administration.
[00340] It is understood that a reasonable estimate of the time to achieve localization can be made by one skilled in the art. Furthermore, the state of localization as a function of time can be followed by imaging the detectable moiety (e.g., a light-emitting conjugate) according to the methods of the invention, such as with a photodetector device. The "photodetector
device" used should have a high enough sensitivity to enable the imaging of faint light from within a mammal in a reasonable amount of time, and to use the signal from such a device to construct an image.
[00341] In cases where it is possible to use light-generating moieties which are extremely bright, and/or to detect light-generating fusion proteins localized near the surface of the subject or animal being imaged, a pair of "night- vision" goggles or a standard high- sensitivity video camera, such as a Silicon Intensified Tube (SIT) camera (e.g., from Hammamatsu Photonic Systems, Bridgewater, N.J.), can be used. More typically, however, a more sensitive method of light detection is required.
[00342] In extremely low light levels the photon flux per unit area becomes so low that the scene being imaged no longer appears continuous. Instead, it is represented by individual photons which are both temporally and spatially distinct form one another. Viewed on a monitor, such an image appears as scintillating points of light, each representing a single detected photon. By accumulating these detected photons in a digital image processor over time, an image can be acquired and constructed. In contrast to conventional cameras where the signal at each image point is assigned an intensity value, in photon counting imaging the amplitude of the signal carries no significance. The objective is to simply detect the presence of a signal (photon) and to count the occurrence of the signal with respect to its position over time.
[00343] At least two types of photodetector devices, described below, can detect individual photons and generate a signal which can be analyzed by an image processor. Reduced-Noise Photodetection devices achieve sensitivity by reducing the background noise in the photon detector, as opposed to amplifying the photon signal. Noise is reduced primarily by cooling the detector array. The devices include charge coupled device (CCD) cameras referred to as "backthinned", cooled CCD cameras. In the more sensitive instruments, the cooling is achieved using, for example, liquid nitrogen, which brings the temperature of the CCD array to approximately -120°C. "Backthinned" refers to an ultra- thin backplate that reduces the path length that a photon follows to be detected, thereby increasing the quantum efficiency. A particularly sensitive backthinned cryogenic CCD camera is the "TECH 512", a series 200 camera available from Photometries, Ltd. (Tucson, Ariz.).
[00344] "Photon amplification devices" amplify photons before they hit the detection screen. This class includes CCD cameras with intensifiers, such as microchannel intensifiers. A microchannel intensifier typically contains a metal array of channels perpendicular to and co-extensive with the detection screen of the camera. The microchannel array is placed
between the sample, subject, or animal to be imaged, and the camera. Most of the photons entering the channels of the array contact a side of a channel before exiting. A voltage applied across the array results in the release of many electrons from each photon collision. The electrons from such a collision exit their channel of origin in a "shotgun" pattern, and are detected by the camera.
[00345] Even greater sensitivity can be achieved by placing intensifying microchannel arrays in series, so that electrons generated in the first stage in turn result in an amplified signal of electrons at the second stage. Increases in sensitivity, however, are achieved at the expense of spatial resolution, which decreases with each additional stage of amplification. An exemplary microchannel intensifier-based single-photon detection device is the C2400 series, available from Hamamatsu.
[00346] Image processors process signals generated by photodetector devices which count photons in order to construct an image which can be, for example, displayed on a monitor or printed on a video printer. Such image processors are typically sold as part of systems which include the sensitive photon-counting cameras described above, and accordingly, are available from the same sources. The image processors are usually connected to a personal computer, such as an IBM-compatible PC or an Apple Macintosh (Apple Computer, Cupertino, Calif), which may or may not be included as part of a purchased imaging system. Once the images are in the form of digital files, they can be manipulated by a variety of image processing programs (such as "ADOBE PHOTOSHOP", Adobe Systems, Adobe Systems, Mt. View, Calif) and printed.
[00347] In an embodiment, the biological sample contains protein molecules from the test subject. One exemplary biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.
[00348] The invention also encompasses kits for detecting the presence of CTLA-4 or a CTLA-4-expressing cell in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting a cancer or tumor cell (e.g., an anti-CTLA-4 scFv or monoclonal antibody) in a biological sample; means for determining the amount of CTLA-4 in the sample; and means for comparing the amount of CTLA-4 in the sample with a standard. The standard is, in some embodiments, a non-cancer cell or cell extract thereof. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect cancer in a sample.
[00349] Other Embodiments
[00350] While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
[00351] The invention is further described in the following examples, which do not limit the scope of the invention described in the claims.
EXAMPLES
[00352] Examples are provided below to facilitate a more complete understanding of the invention. The following examples illustrate the exemplary modes of making and practicing the invention. However, the scope of the invention is not limited to specific embodiments disclosed in these Examples, which are for purposes of illustration only, since alternative methods can be utilized to obtain similar results.
EXAMPLE 1
[00353] Described herein are anti-CTLA-4 antibodies identified via phage display that block CTLA-4/CD80 binding. Further, a yeast display library was also generated from this panning campaign to further interrogate the results of the 2nd and 3rd rounds of panning. After sorting clones that bound higher than the bulk, clones were sequenced and additional clones were identified that demonstrate an improved binding curve compared to the original ones found in the ELISA screens of the third round.
[00354] Embodiments herein can have commercial applications as a stand-alone antibody therapy or in combination with other therapies.
EXAMPLE 2 - aCTLA-4 abs from PMPL panning (first group)
[00355] As shown in FIG. 1, anti-CTLA-4 phage binding assay was performed. Assay performed was medium-scale phagemid rescue using PEG + NaCl to precipitate out the phages and purify them.
[00356] With the purified phage, a binding curve from ELISA data was created. We diluted each of the 9 phage PMPL candidates + E1-D7 starting at 2E13 phagemid particles/mL and decreasing 5 fold. We added these phages in triplicates for CTLA-4 Fc- coated plate and CAIX Fc coated plate.
[00357] As shown in FIG. 2, FACS confirm that CTLA-4 phages can bind to CTLA-4 expressing 1G5 Jurkat cells. The negative control was cells + secondary antibody (red box), and the positive comparison/control was current E1-D7 candidate (green box).
[00358] For the purposes of filtering out candidates, we will consider any CTLA-4 phage candidate that has over 25% positive cells as positive. Out of our 9 possible phage candidates, there was only one comparable candidate B10 (circled in blue) as it is over 75%
positive. There were also some partial positives, these are circled in orange and are B6 and
C12, which are over 25% positive.
EXAMPLE 3
[00359] Soluble proteins utilized herein include:
[00360] Human CTLA-4 Human CTLA-4, His Tag (CT4-H5229) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # NP_005205.2)
1 maclgfqrhk aqlnlatrtw pctll ffll f ipvfckamhv aqpavvlas s rgias fvcey 61 aspgkatevr vtvlrqadsq vtevcaatym mgneltfldd s ictgts sgn qvnltiqglr 121 amdtglyick velmypppyy Igigngtqiy vidpepcpds dfllwilaav s sgl ffys fl 181 Itavs ls kml kkrsplttgv yvkmpptepe cekqfqpyfi pin
[00361] Mouse CTLA-4, His Tag (CT4-M52H5) is expressed from human 293 cells (HEK293). It contains AA Glu 36 - Phe 162 (Accession # NP_033973).
1 maclglrryk aqlqlps rtw pfvalltll f ipvfseaiqv tqpsvvlas s hgvas fpcey 61 spshntdevr vtvlrqtndq mtevcattft e kntvgfldy pfcsgtfnes rvnltiqglr 121 avdtglylck velmypppyf vgmgngtqiy vidpepcpds dfllwilvav s lgl ffys fl 181 vtavs ls kml kkrsplttgv yvkmpptepe cekqfqpyfi pin
[00362]
[00363] Full length CTLA4 was cloned using cDNA from Transomic (BC074893)
EXAMPLE 4 - aCTLA-4
[00364] CTLA4 Overview:
[00365] -Protein receptor that functions as an immune checkpoint
[00366] -Overall structure: Extracellular V domain, Transmembrane domain, cytoplasmic tail
[00367] -Homodimer when membrane-bound: Monomer in soluble form
[00368] CTLA4 Binding:
[00369] -CD28 homolog
[00370] -binds to CD-80/86 (B7-1/2)
[00371] -highly conserved MYPPY motif involved in binding
[00372] Mechanisms to Suppress Immune Response (Fig. 15)
[00373] -Still much debate: Ligand competition, negative signaling, ligand removal, effects on T cell mobility
[00374] Background (Fig. 23):
[00375] - T cells are important mediators to anti-tumor immunity
[00376] - They express inhibitory immune checkpoints: these immune checkpoints serve to limit T cell activation, preventing collateral damage to the body by unrestrained T cell activity
[00377] - PD1 protein is expressed on the surface of T cells: Upon ligation to its ligands PDL-1 and PDL-2, a negative pathway is promoted to inhibit T cell function [00378] - Upon ligation to its ligands PDL-1 and PDL-2, a negative pathway is promoted to inhibit T cell function: Tumor cells also express PDL1 which can facilitate tumor escape.
[00379] MLR Assay (Fig. 24):
[00380] - Co-culture of CD4+ T cells with monocyte-derived DCs each from different donors: Allorecognition of the dendritic cells leads to activation of T cells
[00381] - DCs expressing PDL1 can suppress T cell activation: Addition of immune checkpoint inhibitors can recover T cell from suppression
[00382] - Investigate whether anti-PDl enhances T cell activation
[00383] - Measure IFNy and IL2 cytokine production, indicators of T cell activation
[00384] Protocol:
[00385] -Isolate CD14+ monocytes using Miltenyi CD14+ microbeads
[00386] - Culture in Miltenyi Mo-DC media (pre-prepared media with GM-CSF +
IL4)
[00387] - Culture for 5 days, then add: TNF-a (1000 U/ml), IL-ip (5 ng/ml), IL-6 (10 ng/ml) and prostaglandin E2 (PGE2) (1 pM) and culture for 2 days to mature DC
[00388] - mMo-DCs express various DC markers that are involved in the formation of immunological synapses between DCs and naive T cells, including CD80, CD86, and MHC II (HLA-DR). Mature Mo-DCs also expressed DC activation markers CD83, CD40, and CCR7
[00389] Protocol Continued:
[00390] - Isolate T cells day of MLR experiment ( CD4+ negative selection kit
StemCell)
[00391] - 100, 000 T cells and 10, 000 MoDC cells per well for MLR
[00392] - Antibodies are added at desired concentration and culture is incubated for 5 days
[00393] - Supernatant is saved for ELISA screening (IL2 and IFNy)
[00394] aCTLA4 Antibodies MLR 1 & 2:
[00395] MLR1:
[00396] - 2 T cell Donors, 2 DC Donors
[00397] - DC cultured for 7 days- Secondary cytokines added on day 5
[00398] - Cells combined and cultured for 4 days
[00399] - Positive control: aPD-1 Antibody
[00400] - Negative control: aSARS2 Antibody
[00401] MLR 2:
[00402] - Testing 2 aCTLA4 antibodies (D7, CIO) in combination with aPD-1 antibody.
[00403] - 4 plates: 2 T cell donors, 2 concentrations of aPDl
[00404] - Used aPD-1 media to make antibody dilutions (starting at lOOnM, 5 4-fold dilutions): 5nM aPD-1 media and lOOnM aPD-1 media
[00405] - 100000 T cells + 10000 MoDC per well
[00406] - 50ul of antibody combined with 50ul T cells first
[00407] - Ab/T cells then added to DC
[00408] - Controls: aPD-1 + cells, aPD-1 high + cells, DC + T cell
[00409] - Incubate for 5 days
[00410] FACS to confirm that our CTLA4 phages can bind to CTLA-4 expressing 1G5 Jurkat cells (Fig. 31)
[00411] - To ensure we were able to find a suitable candidate, we went back and screened a 2nd plate of CTLA4 PMPL phage colonies and combined them with data from plate El. All unique colonies were cloned into scFv-Fc expression vectors and transfected into Expi293F cells for high throughput screening via Octet.
[00412] - SA sensors were loaded with biotinyated CTLA4. scFv-Fc cone in expi293 supernatant was measured via IgG quantification ELISA (Bethyl) and used to normalize samples. Binding of scFv-Fc in sup was measured using an OctetRed96.
[00413] Non-Limiting Examples of Categories Considered analyzing data here:
[00414] Very Important
[00415] 1. CD80 blockade
[00416] 2. CD86 blockade
[00417] 3. Dissociation constant (Kd)
[00418] Moderately Important
[00419] 1. Mouse Cross Reactivity
[00420] Of low Importance
[00421] 1. Response
[00422] Exemplary Selected Candidate:
[00423] E1-A8
[00424] Non-Limiting Reasons for Candidate Selection:
[00425] Shows highest CD80 blockade amongst the shortlisted candidates
[00426] CD86 blockade is comparable to Ipilimumab
[00427] Shows Significant Cross-Reactivity with Mouse CTLA4
[00428] Has higher Response than both Ipilimumab and E1-D7
[00429] Shortcomings:
[00430] Shows a relatively higher dissociation rate when compared to most other antibodies tested
[00431] Notes:
[00432] E1-A8 has an identical heavy chain to E2-A4 which shows amongst the highest response rates and a low dissociation constant.
[00433] E1-A8 is derived from the same V gene (IGHV3) but a different allele as
Ipilimumab
EXAMPLE 5 - Engineering and Characterization of an antiPDl/anti-CTLA4 bispecific antibody
[00434] Dual Checkpoint Blockade by Bispecific Antibodies (Fig. 53):
[00435] Without wishing to be bound by theory, advantages can comprise: lower therapeutic dosage, cooperative binding, targeted therapy, and reduced manufacturing cost.
[00436] Non-limiting Overview of goals described herein:
[00437] 1. Discovery and characterization of new anti-CTLA4 antibody:
[00438] 1A: Kinetic Screening and Characterization
[00439] IB: Epitope binning
[00440] 1C: Cell binding assay
[00441] ID: Biological assay
[00442] 2. Engineering and Characterization of antiPDl/anti-CTLA4 bispecific antibody
[00443] 3. Characterization of antiPDl/anti-CTLA4 bispecific antibody as a CAR T payload
[00444] hCTLA2 ELISA binding curve data and results (Fig.56 panel A):
[00445] -ELISA binding curve to demonstrate binding affinity of anti-CTLA4 candidates to hCTLA4.
[00446] - All candidates have comparable binding affinity to hCTLA4 at the highest concentration.
[00447] - Most candidates show comparable binding affinity to ipilimumab
[00448] -Top 3: I, J, H
[00449] -A, E, I have the best saturating concentrations
[00450] mCTLA4 ELISA binding curve data and results (Fig. 56 Panel B)
[00451] - Candidates that show high cross-reactivity: E, F, A
[00452] - Candidates that show moderate cross-reactivity: J, H
[00453] - Ipilimumab and Biolegend anti-CTLA4 do not show cross-reactivity true to the literature
[00454] BSA Negative Curve (Fig. 56 Panel C)
[00455] -indicates binding affinity of anti-CTLA4 candidates to BSA (negative control)
[00456] Binding affinity of anti-CTLA4 candidates to CTLA4+ Jurkat Cells (Fig. 64)
[00457] - Apparent inconsistency in the binding affinities of the antibodies to cells vs. to soluble protein.
[00458] - J and H have a much higher binding affinity and a lower saturating concentration to Ipilimumab
[00459] - E and F have comparable binding characteristics to ipilimumab
[00460] Non-Limiting, Exemplary Conclusions from Data Described Herein:
[00461] - 5 anti-CTLA4 antibodies screened from a library of different candidates show:
[00462] a. significant binding affinity to CTLA4
[00463] b. ability to block CTLA4 interaction with CD80/86
[00464] c. biological functional relevance by facilitating CD80/CD28 signaling in effector cells.
[00465] Without wishing to be bound by theory, the following experiments can supplement the data described herein:
[00466] - Further experiments with the bispecific format to determine the most suited anti-CTLA4 antibody for the antiPDl/anti-CTLA4 bispecific
[00467] - In-vitro assays to characterize the Bispecific antibody
[00468] - Characterization and efficacy studies of the Bispecific as a payload in CAR
T cell therapy.
EQUIVALENTS
[00469] Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.
Claims (1)
- What is claimed:1. An isolated antibody or fragment thereof that binds to human Cytotoxic T- Lymphocyte Associated Protein 4 (CTLA-4) comprising:(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or(b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or(c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or(d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or(e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or(f) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or(g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or(h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or(i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or(j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence ofSEQ ID NO: 90; or(k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or(l) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or(m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or(n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or(o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid- 171 - sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or(p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or(q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or(r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or(s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or(t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid- 172 - sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or(u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481; or(v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or(w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or(x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or(y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid- 173 - sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or(z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or(aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or(bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or(cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or(dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid- 174 - sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or(ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or(ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or(gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or(hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or(ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or(jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or(kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or(11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927. An isolated scFv antibody, that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising:(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or(b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or(c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or(d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or(e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or(I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or(g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the- 177 - amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or(h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or(i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or(j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or(k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or(l) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid- 178 - sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence ofSEQ ID NO: 96; or(m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or(n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or(o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or(p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or(q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid- 179 - sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or(r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or(s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or(t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or(u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481; or(v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid- 180 - sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or(w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or(x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or(y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or(z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or(aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid- 181 - sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or(bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or(cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or(dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or(ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or(ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid- 182 - sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or(gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or(hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or(ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or(jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or(kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid- 183 - sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or(11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927. An isolated antibody or fragment thereof that binds to human Cytotoxic T- Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, and 1023 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 368, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, and 1024. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 1001, 1003, 1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, and 1023 and a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 368, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 410, 412, 1002, 1004, 1006, 1008, 1010, 1012, 1014, 1016, 1018, 1020, 1022, and 1024. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 184 - amino acid sequence about 95% identical to SEQ ID NO: 1, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 2. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 2. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 3, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 4. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 3, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 4. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 5, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 6. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 5, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 6. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 185 - amino acid sequence about 95% identical to SEQ ID NO: 7, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 8. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 7, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 8. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 9, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 10. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 9, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 10. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 11, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 12. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 11, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 12. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 13, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 14. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 13, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 14. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 15, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 16. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 15, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 16. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 17, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 18. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 17, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 18. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 19, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 20. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 19, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 20. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 21, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 22. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 21, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 22. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 23, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 24. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 23, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 24. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 188 - amino acid sequence about 95% identical to SEQ ID NO: 385, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 386. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 385, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 386. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 387, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 388. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 387, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 388. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 389, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 390. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 389, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 390. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 189 - amino acid sequence about 95% identical to SEQ ID NO: 391, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 392. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 391, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 392. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 393, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 394. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 393, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 394. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 395, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 396. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 395, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 396. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 190 - amino acid sequence about 95% identical to SEQ ID NO: 397, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 398. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 397, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 398. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 399, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 400. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 399, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 400. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 401, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 402. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 401, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 402. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 191 - amino acid sequence about 95% identical to SEQ ID NO: 403, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 404. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 403, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 404. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 405, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 406. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 405, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 406. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 407, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 408. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 407, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 408. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 192 - amino acid sequence about 95% identical to SEQ ID NO: 409, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 410. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 409, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 410. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 411, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 412. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 411, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 412. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1001, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1002. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1001, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1002. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 193 - amino acid sequence about 95% identical to SEQ ID NO: 1003, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1004. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1003, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1004. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1005, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1006. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1005, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1006. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1007, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1008. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1007, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1008. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 194 - amino acid sequence about 95% identical to SEQ ID NO: 1009, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1010. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1009, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1010. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1011, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1012. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1011, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1012. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1013, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1014. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1013, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1014. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 195 - amino acid sequence about 95% identical to SEQ ID NO: 1015, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1016. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1015, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1016. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1017, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1018. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1017, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1018. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1019, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1020. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1019, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1020. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an- 196 - amino acid sequence about 95% identical to SEQ ID NO: 1021, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1022. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1021, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1022. An isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1023, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1024. An isolated scFv antibody that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4) comprising a heavy chain, a light chain, or a combination thereof, wherein the heavy chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1023, and the light chain comprises an amino acid sequence about 95% identical to SEQ ID NO: 1024. An isolated monoclonal antibody or antigen-binding fragment of claims 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, or 79, wherein the isolated monoclonal antibody or antigen-binding fragment comprises a wildtype Fc or a modified Fc. An isolated bispecific antibody comprising an antibody or fragment of any one of claims 1-81, and a second antigen-binding fragment having specificity to a molecule on an immune cell. The bispecific antibody of claim 82, wherein the molecule is selected from the group consisting of CCR4, B7H3, B7H4, CD27, CD28, CD40, CD40L, CD47, CD122, CTLA-4, GITR, GITRL, ICOS, ICOSL, LAG-3, LIGHT, OX-40, OX40L, PD-1, TIM3, 4- IBB, TIGIT, VISTA, HEVM, BTLA, CD47, PDL1, MICA, MICB, and KIR.- 197 - The bispecific antibody of claim 82, wherein the fragment and the second fragment each is independently selected from a Fab fragment, a single-chain variable fragment (scFv), or a single-domain antibody. The bispecific antibody of claim 82, further comprising a Fc fragment. The bispecific antibody of claim 85, wherein the Fc fragment comprises a wildtype Fc fragment or a modified Fc fragment. A nucleic acid encoding the antibody according to any one of claims 1-81. A nucleic acid encoding the bispecific antibody according to any one of claims 82-86. A pharmaceutical composition comprising the antibody or fragment thereof according to any one of claims 1-81, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition of claim 89, further comprising at least one additional therapeutic agent. The pharmaceutical composition of claim 90, wherein the therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine. A pharmaceutical composition comprising the bispecific antibody according to any one of claims 82-86, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition of claim 92, further comprising at least one additional therapeutic agent. The pharmaceutical composition of claim 93, wherein the therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine. An isolated cell comprising one or more polynucleotide(s) encoding the antibody or fragment thereof of any one of claims 1-81. An isolated cell comprising one or more polynucleotide(s) encoding the bispecific antibody or fragment thereof of any one of claims 82-86. The isolated cell of claim 95 or claim 96, wherein the isolate cell is an immune cell.- 198 - The isolated cell of claim 97, wherein the immune cell is a T cell, an NK cell, or a B cell. A vector comprising the nucleic acid of claims 87 or 88. A cell comprising the vector of claim 99. The cell of claim 100, wherein the cell is an immune cell. The cell of claim 101, wherein the immune cell is a T cell, an NK cell, or a B cell. A method of treating a cancer in a subject in need thereof, the method comprising administering to a subject a therapeutically effective amount of the CTLA-4 antibody or fragment thereof of any one of claims 1-81. A method of treating a cancer in a subject in need thereof, the method comprising administering to a subject a therapeutically effective amount of the CTLA-4 bispecific antibody of any one of claims 82-86. A chimeric antigen receptor (CAR) comprising an intracellular signaling domain, a transmembrane domain and an extracellular domain, wherein the extracellular domain is an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), wherein the monoclonal antibody or fragment thereof comprises a heavy chain, light chain, or combination thereof, wherein the heavy chain comprises(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or(b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid- 199 - sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence ofSEQ ID NO: 66; or(c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or(d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or(e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or(I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or(g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid- 200 - sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or(h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or(i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or(j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or(k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or(l) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid- 201 - sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence ofSEQ ID NO: 96; or(m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or(n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or(o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or(p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or(q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid- 202 - sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or(r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or(s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or(t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or(u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481; or(v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid- 203 - sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or(w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or(x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or(y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or(z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or(aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid- 204 - sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or(bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or(cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or(dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or(ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or(ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid- 205 - sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or(gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or(hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or(ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or(jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or(kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid- 206 - sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or(11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927. The CAR of claim 105, wherein the transmembrane domain further comprises a stalk region positioned between the extracellular domain and the transmembrane domain. The CAR or claim 105, wherein the transmembrane domain comprises CD28. The CAR of claim 105, further comprising one or more additional costimulatory molecules positioned between the transmembrane domain and the intracellular signaling domain The CAR of claim 105, wherein the costimulatory molecules is CD28, 4-1BB, ICOS, or 0X40. The CAR of claim 105, wherein the intracellular signaling domain comprises a CD3 zeta chain. The CAR of claim 105, wherein the antibody is a Fab or a scFV. A nucleic acid encoding the CAR of any one of claims 105-111. The nucleic acid of claim 112, further comprising a nucleic acid encoding a polypeptide positioned after the intracellular signaling domain. The nucleic acid of claim 113, wherein the polypeptide is an antibody or a cytokine. The nucleic acid of claim 114, wherein the antibody is a scFV. A nucleic acid encoding a CAR, wherein the CAR comprises an intracellular signaling domain, a transmembrane domain and an extracellular domain, further comprising a nucleic acid encoding a polypeptide positioned after the intracellular signaling domain,- 207 - wherein the polypeptide comprises an isolated monoclonal antibody or antigen-binding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), wherein the monoclonal antibody or fragment thereof comprises a heavy chain, light chain, or combination thereof, wherein the heavy chain comprises(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or(b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or(c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or(d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or- 208 - (e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or(I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or(g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or(h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or(i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or- 209 - (j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or(k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or(l) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or(m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or(n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or- 210 - (o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or(p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or(q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or(r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or(s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or- 211 - (t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or(u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481; or(v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or(w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or(x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or- 212 - (y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or(z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or(aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or(bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or(cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or- 213 - (dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or(ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or(ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or(gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or(hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or- 214 - (ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or(jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or(kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or(11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927. A vector comprising the nucleic acid of any one of claims 112-116. A cell comprising the vector of claim 117. The cell of claim 118, wherein the cell is an immune cell. A genetically engineered cell which expresses and bears on the cell surface membrane the chimeric antigen receptor of any one of claims 105-111.- 215 - The cell of claim 120, wherein the immune cell is a T-cell, an NK cell or a B cell. The cell of claim 121, wherein the T cell is CD4+ or CD8+. The genetically engineered cell of claim 122, which comprises a mixed population of CD4+ and CD8 cells+. A genetically engineered cell which express and bear on the cell surface membrane a chimeric antigen receptor, and which is further engineered to express and secrete a polypeptide, wherein polypeptide is an isolated monoclonal antibody or antigenbinding fragment thereof that binds to human Cytotoxic T-Lymphocyte Associated Protein 4 (CTLA-4), wherein the monoclonal antibody or fragment thereof comprises a heavy chain, light chain, or combination thereof, wherein the heavy chain comprises(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 25, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 26, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 27, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 63; or(b) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 28, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 29, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 30, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 66; or(c) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 33, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 69; or- 216 - (d) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 70, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 72; or(e) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 38, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 39, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 73, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 75; or(I) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 41, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 42, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 78; or(g) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 44, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 45, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 79, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 81; or(h) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 46, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 47, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 48, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 82, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 84; or- 217 - (i) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 49, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 50, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 51, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 85, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 87; or(j) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 88, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 90; or(k) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 55, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 56, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 57, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 91, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 93; or(l) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 58, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 59, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 60, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 94, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 96; or(m) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 413, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 414, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 415, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 455, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 456, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 457; or- 218 - (n) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 416, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 417, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 418, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 458, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 459, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 460; or(o) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 419, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 420, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 421, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 461, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 462, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 463; or(p) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 422, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 423, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 424, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 464, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 465, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 466; or(q) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 425, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 426, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 427, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 467, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 468, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 469; or(r) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 428, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 429, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 430, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 470, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 471, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 472; or- 219 - (s) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 431, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 432, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 433, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 473, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 474, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 475; or(t) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 434, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 435, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 436, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 476, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 477, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 478; or(u) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 437, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 438, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 439, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 479, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 480, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 481; or(v) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 440, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 441, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 442, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 482, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 483, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 484; or(w) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 443, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 444, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 445, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 485, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 486, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 487; or- 220 - (x) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 446, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 447, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 448, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 488, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 489, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 490; or(y) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 449, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 450, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 451, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 491, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 492, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 493; or(z) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 452, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 453, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 454, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 494, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 495, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 496; or(aa) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 857, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 858, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 859, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 892, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 893, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 894; or(bb) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 860, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 861, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 862, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 895, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 896, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 897; or- 221 - (cc) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 863, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 864, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 865, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 898, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 899, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 900; or(dd) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 866, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 867, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 868, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 901, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 902, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 903; or(ee) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 869, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 870, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 871, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 904, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 905, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 906; or(ff) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 872, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 873, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 874, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 907, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 908, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 909; or(gg) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 875, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 876, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 877, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 910, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 911, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 912; or- 222 - (hh) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 878, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 1000, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 879, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 913, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 914, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 915; or(ii) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 880, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 881, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 882, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 916, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 917, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 918; or(jj) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 883, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 884, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 885, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 919, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 920, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 921; or(kk) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 886, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 887, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 888, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 922, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 923, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 924; or(11) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 889, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 890, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 891, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 925, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 926, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 927.- 223 -
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163282887P | 2021-11-24 | 2021-11-24 | |
US63/282,887 | 2021-11-24 | ||
PCT/US2022/050934 WO2023097024A1 (en) | 2021-11-24 | 2022-11-23 | Antibodies against ctla-4 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2022396272A1 true AU2022396272A1 (en) | 2024-06-06 |
Family
ID=84901675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2022396272A Pending AU2022396272A1 (en) | 2021-11-24 | 2022-11-23 | Antibodies against ctla-4 and methods of use thereof |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4436998A1 (en) |
KR (1) | KR20240123846A (en) |
AU (1) | AU2022396272A1 (en) |
CA (1) | CA3238936A1 (en) |
WO (1) | WO2023097024A1 (en) |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
WO1988001513A1 (en) | 1986-08-28 | 1988-03-10 | Teijin Limited | Cytocidal antibody complex and process for its preparation |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69029036T2 (en) | 1989-06-29 | 1997-05-22 | Medarex Inc | SPECIFIC REAGENTS FOR AIDS THERAPY |
US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
JP3068180B2 (en) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | Generation of heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE158021T1 (en) | 1990-08-29 | 1997-09-15 | Genpharm Int | PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
JPH06507398A (en) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Heterogeneous conjugate antibody for treatment of HIV infection |
US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
DE69233482T2 (en) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
ES2136092T3 (en) | 1991-09-23 | 1999-11-16 | Medical Res Council | PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES. |
ES2301158T3 (en) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | XENOGENIC ANTIBODY PRODUCTION. |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
DE69329503T2 (en) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutic use of chimeric and labeled antibodies directed against a differentiation antigen, the expression of which is restricted to human B lymphocyte, for the treatment of B cell lymphoma |
JPH10501681A (en) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | Nucleic acid delivery systems and methods for their synthesis and use |
DE69637481T2 (en) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Human antibodies to IL-8 derived from immunized Xenomae |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
KR20080059467A (en) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
CZ303703B6 (en) * | 1998-12-23 | 2013-03-20 | Pfizer Inc. | Monoclonal antibody or fragment-binding antigen thereof, pharmaceutical composition in which the antibody or fragment is comprised, a cell line producing the antibody or fragment, process for preparing the antibody, isolated nucleic acid encoding hea |
EP3214175A1 (en) * | 1999-08-24 | 2017-09-06 | E. R. Squibb & Sons, L.L.C. | Human ctla-4 antibodies and their uses |
WO2005018572A2 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
US9111624B2 (en) | 2013-03-22 | 2015-08-18 | Katsuyuki Fujita | Semiconductor memory device |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
WO2017156178A1 (en) | 2016-03-08 | 2017-09-14 | Maverick Therapeutics, Inc. | Inducible binding proteins and methods of use |
US20200017588A1 (en) | 2016-10-14 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | Modular tetravalent bispecific antibody platform |
WO2018160754A2 (en) | 2017-02-28 | 2018-09-07 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
EP3679068A2 (en) | 2017-09-08 | 2020-07-15 | Maverick Therapeutics, Inc. | CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS |
WO2021208838A1 (en) * | 2020-04-13 | 2021-10-21 | Biosion Inc. | Antibodies binding ctla4 and uses thereof |
-
2022
- 2022-11-23 CA CA3238936A patent/CA3238936A1/en active Pending
- 2022-11-23 WO PCT/US2022/050934 patent/WO2023097024A1/en active Application Filing
- 2022-11-23 KR KR1020247020850A patent/KR20240123846A/en unknown
- 2022-11-23 AU AU2022396272A patent/AU2022396272A1/en active Pending
- 2022-11-23 EP EP22840432.3A patent/EP4436998A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3238936A1 (en) | 2023-06-01 |
WO2023097024A1 (en) | 2023-06-01 |
KR20240123846A (en) | 2024-08-14 |
EP4436998A1 (en) | 2024-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11942149B2 (en) | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof | |
US11840553B2 (en) | Anti-CD47 antibodies and methods of use thereof | |
AU2018226425A1 (en) | Human Monoclonal Anti-PD-L1 Antibodies and Methods of Use | |
US11203646B2 (en) | Anti-CD3 epsilon antibodies and methods of use thereof | |
CN116082506A (en) | Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof | |
US20230127123A1 (en) | Antibodies against pd-l1 and methods of use thereof | |
US20220249640A1 (en) | Antibodies against pd-1 and methods of use thereof | |
EP4436998A1 (en) | Antibodies against ctla-4 and methods of use thereof | |
US20220275088A1 (en) | Antibodies against pd-1 and methods of use thereof | |
WO2024039670A1 (en) | Antibodies against cldn4 and methods of use thereof | |
US20240254234A1 (en) | PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION | |
WO2024039672A2 (en) | Antibodies against msln and methods of use thereof | |
WO2024211900A1 (en) | Il-10 receptor antibodies and methods of use thereof | |
WO2024129862A2 (en) | Checkpoint modulators for enhancing immunotherapy |